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Gene Expression Profile Reveals the Novel Repression of Heat Shock Protein 
Expression by TNIP1 in Keratinocytes 
Vincent P. Ramirez, PhD 
University of Connecticut, 2014 
The TNFα-induced protein 3-interacting protein 1 (TNIP1) protein 
represses various receptor-mediated signaling pathways, ranging from 
transmembrane to nuclear receptors. Increased TNIP1 expression results in 
blocking the TNFα-induced NF-κB activation or repressing peroxisome 
proliferator activated receptor and retinoic acid receptor activity. These 
transcription factors play key roles in regulating inflammation and inflammatory 
diseases. A growing number of references have linked TNIP1 SNPs and 
increased expression in psoriasis, a chronic inflammatory disease characterized 
by keratinocyte hyperproliferation and incomplete differentiation. However, 
TNIP1’s exact role is not yet known. To determine the genes and biological 
functions regulated by TNIP1 in keratinocytes, we overexpressed TNIP1 in 
cultured keratinocytes and performed a gene expression microarray analysis. 
Reduced expression of most genes was observed, including several heat shock 
proteins (HSP). These results suggest TNIP1 could regulate the cell stress 
response. However, its exact role in this process and the mechanism of the 
TNIP1-mediated transcriptional repression is not yet characterized. 
We examined the TNIP1 repression of HSPA6 (also named HSP70B’) to 
model the repression on all HSPs. Since the transcriptional regulation of HSPA6 
has not yet been fully characterized, we examined the factors contributing to its 
promoter activation. We found that a novel AP1 site and heat shock element 
upstream of previously recognized sites contribute to its basal and stress 
inducibility, respectively. To determine the mechanism of TNIP1’s repression on 
HSPA6, we hypothesized that TNIP1 acts on PPAR, RAR or NF-κB to reduce the 
expression of HSPs. We observed TNIP1 does not act through these 
transcription factors, but possibly through a novel, yet uncharacterized pathway. 
Additionally, we assessed the effect of TNIP1 on keratinocyte proliferation and 
differentiation. We found that a chronic, but not acute, overexpression of TNIP1 
blocks keratinocyte cell growth to possibly through decreasing the HSP 
chaperone function.  
 
 
 
 
  
 
 
 
Gene Expression Profile Reveals the Novel Repression of 
Heat Shock Protein Expression by TNIP1 in Keratinocytes 
 
 
 
 
 
Vincent P. Ramirez 
B.S. University of California, Davis, 2004 
 
 
 
 
 
 
A Dissertation 
Submitted in Partial Fulfillment of the 
Requirements for the Degree of 
Doctor of Philosophy 
at the 
University of Connecticut 
2014  
 ii 
 
APPROVAL PAGE 
Doctor of Philosophy Dissertation 
 
Gene Expression Profile Reveals the Novel Repression of 
Heat Shock Protein Expression by TNIP1 in Keratinocytes 
 
 
Presented by 
Vincent P. Ramirez, B.S.  
 
 
Major Advisor __________________________________________________ 
Dr. Brian J. Aneskievich 
 
Associate Advisor 
__________________________________________________ 
Dr. Theodore Rasmussen 
 
Associate Advisor 
__________________________________________________ 
Dr. Charles Giardina 
 
 
 
University of Connecticut 
2014 
 iii 
 
Dedication 
To the Ramirez, Pascual, Panganiban and Titong families: thank you for 
all your support throughout this journey. 
  
  
 iv 
 
Acknowledgements 
I would like to give my sincerest thanks to my major advisor Dr. Brian J. 
Aneskievich for giving me the opportunity to join his laboratory as a graduate 
student. With his guidance and training, I grew into the scientist I am today. I 
would also like to thank my associate advisors Dr. Charles Giardina and Dr. 
Theodore Rasmussen for their time and efforts in advising me throughout my 
research project. I would especially like to thank Dr. Giardina for his expertise 
and input on the intricacies and technicalities of the heat shock protein world. 
I am thankful for the help and advice given by the past and present 
members of the Aneskievich lab. First, I would like to thank Carmen Zhang for 
training me in various aspects of the lab and for starting the microarray project by 
doing the initial TNIP1-overexpression. I also want to thank the past Aneskievich 
lab graduate students, Priscilla Encarnacao, Igor Gurevich and Nidhish Francis, 
for their suggestions and comments to help me with the TNIP1-HSP project. 
Also, thanks to my undergraduate and Pharm.D mentees Mike Stamatis for 
generating many of the luciferase constructs used for these experiments, 
Anastasia Shmukler for performing some of the qPCR and MTS assays, Tom 
Walcyzk for keeping the lab in perfect condition, and Hank Ng for his assistance 
with the TSS project. I also could not have completed the project without the 
work and results generated by Nora McHugh.  
I am very grateful to my former supervisors Dr. Sarah Jaw-Tsai for 
teaching me about pharmacology and pharmacokinetics and encouraging me to 
 v 
 
pursue my graduate studies and Michele Bauer for giving me a start in laboratory 
research. 
I would like to acknowledge the financial support I received from the 
UConn School of Pharmacy, Center for Regenerative Biology, and Molecular and 
Cellular Biology, and Society of Toxicology, as well as the NIH and UConn 
Research foundation grants awarded to Dr. Aneskievich. 
I would like to thank my family and friends for their support and 
encouragement throughout my time in graduate school. Lastly, I would like to 
give a heartfelt thank you to my beautiful and wonderful wife, Alley. Without you 
by my side to help and support me before and during graduate school, I would 
not have succeeded. Thank you for all you have done with and for me.  
  
  
 vi 
 
Table of contents 
  Page 
Title Page  i 
Approval Page  ii 
Dedication  iii 
Acknowledgements  iv 
Table of Contents  vi 
List of Figures  viii 
List of Tables  x 
List of Abbreviations  xi 
   
Chapter 1 Introduction 1 
 Skin anatomy and keratinocyte biology 1 
 TNFα-Induced Protein 3-Interacting Protein 1 
(TNIP1) 
8 
 Heat Shock Proteins 20 
 Summary 23 
   
Chapter 2 TNIP1 modulates heat shock protein expression 
and the stress response 
25 
 Abstract 25 
 Introduction 27 
 Materials and Methods 30 
 Results 35 
 Discussion 46 
   
   
   
   
   
   
 vii 
 
Chapter 3 Transcriptional regulation of HSPA6 in basal 
and stressed conditions 
50 
 Abstract 50 
 Introduction 52 
 Materials and Methods 55 
 Results 62 
 Discussion 86 
   
Chapter 4 TNIP1-HSP mechanism of repression and 
overall keratinocyte consequences 
92 
 Abstract 92 
 Introduction 93 
 Materials and Methods 96 
 Results 100 
 Discussion 111 
   
Chapter 5 Summary, conclusions and future directions 114 
 Summary and conclusions 114 
 Future directions 119 
   
Appendix 1 TNIP1 protein expression up to 96 hours 122 
Appendix 2 Microarray results from TNIP1 overexpression 123 
Appendix 3 Protocol for making HSPA6 promoter constructs 130 
Appendix 4 TNIP1 transcriptional start site 136 
Appendix 5 Experiment numbers for each figure 138 
   
References  139 
 
 
 
 viii 
 
List of Figures 
  Page 
1.1 Illustration of the skin 6 
1.2 Illustration of the epidermis and its keratinocyte layers 7 
1.3 TNIP1-mediated signaling pathways 17 
2.1 Validation of TNIP1 overexpression 36 
2.2 TNIP1 overexpression microarray results 38 
2.3 Ingenuity Pathway Analysis clustering of genes with significant 
expression change 
39 
2.4 DAVID clustering of genes with significant expression change 42 
2.5 Effect of TNIP1 overexpression on HSPs in HaCaT KCs 43 
2.6 Effect of TNIP1 overexpression on KC differentiation markers in 
NHEKs 
44 
2.7 Effect of TNIP1 overexpression on HSPs in NHEKs 45 
3.1 Basal and heat-inducible expression of HSPA6 in HaCaT KCs 63 
3.2 Basal and heat-inducible expression of HSPA1A in HaCaT KCs 64 
3.3 Expression of HSPA6 in various cell types 65 
3.4 Native restriction enzyme sites within the HSPA6 3kb promoter 67 
3.5 In silico analysis of the HSPA6 3kb promoter 68 
3.6 Determining the transcriptionally regulated regions within the 
HSPA6 promoter 
71 
3.7 Localizing the repressible region within the HSPA6 promoter 72 
3.8 Localizing the basal and inducible regions within the HSPA6 
promoter 
73 
3.9 Searching for transcription factor binding sites between -346 to -216 
bp region of the HSPA6 promoter 
75 
3.10 Characterization of the -244 bp AP1 site 76 
3.11 EMSA binding analysis of AP1 proteins c-Jun and c-Fos to the -244 
AP1 site 
77 
   
 ix 
 
3.12 Searching for heat responsive elements between -346 to -216 bp 
region of HSPA6  
80 
3.13 Characterization of the -284 bp HSE 81 
3.14 EMSA binding analysis of HaCaT HSF proteins to the -284 bp HSE  82 
3.15 EMSA binding analysis of HaCaT HSF proteins to a consensus HSE 83 
3.16 EMSA binding analysis of HeLa HSF proteins to the -284 bp HSE 84 
3.17 EMSA binding analysis of HeLa HSF proteins to a consensus HSE 85 
4.1 In silico analysis of the HSPA6 3kb promoter searching for TNIP1-
repressed transcription factors 
101 
4.2 Analysis of the HSPA6 promoter truncation constructs 102 
4.3 Analysis of the HSPA6 promoter deletion constructs 106 
4.4 Effect of TNIP1 overexpression on HSPs in heat stressed HaCaT 
KCs 
108 
4.5 Effect of “short term” increased TNIP1 levels on HaCaT KCs viability 
and growth 
109 
4.6 Effect of “long term” increased TNIP1 levels on HaCaT KCs viability 
and growth 
110 
   
 
  
 x 
 
List of Tables 
  Page 
1.1 TNIP1 and associated diseases 18 
1.2 Experimentally altered TNIP1 and the resulting phenotypes 19 
2.1 List of qPCR primers for the microarray 34 
3.1 Site-directed mutagenesis primer sequences.  60 
3.2 Oligomers used for EMSA probes 61 
4.1 List of top predicted transcription factor binding sites within the -216 
to -70 bp region of the HSPA6 promoter 
109 
   
 
  
 xi 
 
List of Abbreviations 
ABIN1 A20 binding and inhibitor of NF-κB 
AP1 Activator protein 1 
C/EBP Ccaat-enhancer binding proteins 
DAVID Database for Annotation, Visualization and Integrated 
Discovery 
DNAJA1 HSP40 (homolog), subfamily A, member 1 
DNAJB1 HSP40 (homolog), subfamily B, member 1 
EMSA Electrophoretic mobility shift assay 
GWAS Genome wide association studies 
HDAC Histone deacetylase 
HSE Heat shock element 
HSF Heat shock transcription factor 
HSP Heat shock protein 
HSPA1A HSP70, subfamily A, member 1A 
HSPA6 HSP70, subfamily A, member 6 (HSP70B’) 
IKK Inhibitor of NF-κB kinase 
IPA Ingenuity Pathway Analysis 
KC Keratinocyte 
luc Luciferase 
mt Mutant 
MZF1 Myeloid zing finger 1 
NEMO NF-κB essential modulator 
NF-κB Nuclear actor κB 
NHEK Normal human epidermal keratinocyte 
NR Nuclear receptor 
PPAR Peroxisome proliferator activated receptor 
RA Rheumatoid arthritis 
RAR Retinoic acid receptor 
RIP140 Receptor interacting protein 140 
RXR Retinoid X receptor 
SLE Systemic lupus erythematosus 
SNP Single nucleotide polymorphism 
SRC1 Steroid receptor coactivator 1 
SSc Systemic sclerosis 
TNFAIP3 TNFα-induced protein 3 
TNFR TNFα receptor 
TNFα Tumor necrosis factor, alpha 
TNIP1 TNFα induced protein 3-interacting protein 1 
UBAN Ubiquitin binding in ABIN and NEMO 
VAN Virion-associated nuclear shuttling protein 
WHN Winged helix transcription factor 
ZFX Zinc finger protein, X-linked 
 
 1 
Chapter 1 
INTRODUCTION 
Skin structure and regulation 
Skin anatomy and keratinocyte biology 
 The skin is the largest organ in our body serving as a first line defense 
from various environmental stressors, including exposure to UV, heat and 
chemicals. It is made up of two layers: the outer epidermal layer and the 
underlying dermal layer (Fig 1.1) (1, 2), each consisting of many specialized cells 
and structures that contribute to the overall health and protective function of the 
skin. The outermost layer, the epidermis, is composed of several different cell 
types, in which approximately 90% are keratinocytes (KC) (3). The remaining 
cells are melanocytes and Langerhans cells, which contribute to skin 
pigmentation and protect the skin during infections, respectively. The epidermis 
can be further subdivided into four major layers – the stratum basale (bottom 
layer), stratum spinosum, stratum granulosum and stratum corneum (top layer) 
(Fig 1.2) (4). The process of cornification, when KC proliferate and differentiate 
from the basal to the cornified cells, is crucial for to generate a tough, resilient 
barrier to separate the body from the harsh environment (2).  
 Epidermal and KC homeostasis are regulated by many different 
endogenous and exogenous factors, including proteins, drugs and UV (5-7). The 
epidermis is at a constant state of flux where new KCs are produced in the 
stratum basale, while old, differentiated KCs are sloughed off from the stratum 
corneum. Proliferative KCs are found in the basal layer, where they are 
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responsible for repopulating the epidermis. When a KC leaves this layer, a 
unique form of programmed cell death, cornification, occurs, where there is a 
turnover of highly specific proteins within each layer of the epidermis, eventually 
resulting in the KC’s death and removal at the top layer (4). Several receptor-
mediated pathways regulate the cornification process, including nuclear 
receptors (NR), tumor necrosis factor alpha (TNFα) receptor (TNFR), epidermal 
growth factor receptor (EGFR), and toll like receptors (TLR).  
 
Keratinocyte regulation by nuclear receptors 
NRs are a superfamily of ligand-activated transcription factors that 
modulate gene transcription. There are over 45 different NRs, each playing key 
roles in regulating many biological functions and processes (8). Many different 
NRs, including but not limited to peroxisome proliferator activated receptors 
(PPAR) and retinoic acid receptors (RAR), contribute to KC differentiation 
process. Equally important to the transcriptional activity of ligand-bound NRs are 
the coregulator proteins they interact with. Coregulators, which are classified as 
either coactivators or corepressors, directly bind NRs through specific amino acid 
motifs. As their name might suggest, coactivators increase NR transcriptional 
activity, facilitated by NR ligand binding. Corepressors, on the other hand, 
mediate the repression of NRs, typically, in absence of a ligand. The regulation of 
NRs, and the possible effect on their target genes, could have a great effect on 
KC homeostasis (9). 
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 The PPAR subfamily of NRs has been shown to enhance KC proliferation 
and differentiation. Ligands for PPARs range from endogenous lipids and their 
derivatives to exogenous therapeutic chemicals targeting a specific subtype(s) of 
PPAR. KCs express all three subtypes (α, β/δ and γ) of PPARs in both basal and 
suprabasal KCs (10). Pharmacological stimulation of PPAR β/δ or γ by isoform 
specific ligands resulted in stimulating KC differentiation, suggesting a pro-
differentiation role in skin physiology (11, 12). On the other hand, PPARα 
activation results in a thinner epidermis, where KC proliferation is blocked but 
differentiation is induced (13). Since each PPAR isoform plays a role in normal 
KC differentiaton and proliferation, its potential role in KC-related diseases were 
also characterized. Psoriasis is classically recognized as epidermal keratinocyte 
hyperproliferation with incomplete differentiation, incomplete barrier formation, 
and immune cell infiltration (14). In psoriasis, PPAR ligand treatment reduced the 
inflammation and restored normal KC physiology (15-17). 
 In contrast to PPARs, the two isoforms of RAR (α and γ) were 
characterized in the skin to represses KC proliferation and differentiation. 
Treatment with retinoids, the ligands for RARs, has shown to prevent proper KC 
differentiation, where the top, cornified layer does not fully form (18). Because of 
this repressive effect, retinoids have been used to treat hyperproliferative 
inflammatory diseases, including psoriasis (19). Since the activation of either 
RAR or PPAR can lead to drastic changes in skin proliferation and differentiation 
in both normal and diseased skin, understanding the mechanisms involved in 
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these regulating NRs activation and repression is crucial to potentially target 
these receptors to maintain or modulate KC homeostasis.  
 
TNFα receptor and keratinocyte cornification 
 The fate of KC proliferation and differentiation in both normal and inflamed 
conditions can also be regulated by altering the TNFR-initiated signaling 
pathway. TNFR is a key transmembrane protein to activate the transcription 
factor NF-κB, which contributes to promoting KC terminal differentiation. 
Classically, the activation of NF-κB is initiated by TNFR and is largely dependent 
on a series of phosphorylation and ubiquitination steps on various cytoplasmic 
proteins. Typically, ubiquitination is part of the proteasome-mediated protein 
degradation pathway; however, there are proteins, including NF-κB essential 
modulator (NEMO; also named inhibitor of NF-κB kinase gamma; IKKγ), whose 
ubiquitination results not only in protein breakdown but also in protein-protein 
interaction and enzyme activation (20). Although not an enzyme itself, 
ubiquitinated NEMO interacts with IKKα and IKKβ in the IKK complex and 
facilitates activation of these kinases. The ubiquitination of NEMO is essential in 
this pathway because without it, the subsequent degradation of IκB and nuclear 
translocation of NF-κB will be blocked. When NF-κB activation was prevented in 
mice, a thickening in the suprabasal KCs was observed; alternatively, when NF-
κB was overexpressed, a hypoplastic epidermal layer was seen (21). In addition 
to activation of NF-κB, TNFR stimulation results in increased expression of pro-
inflammatory cytokines, including IL-6 and IL-8, which are also involved in 
regulating KC proliferation (22). These results indicate that the activation of 
 5 
TNFR and NF-κB contribute to the generation of a normal, stratified epidermal 
layer. Overall, understanding the regulatory proteins involved in the TNFR and 
NR pathways is essential to determine the possible fate of epidermal KCs. Our 
lab discovered and characterized a novel NR corepressor, TNFα-induced protein 
3 (TNFΑIP3)-interacting protein 1 (TNIP1), and aimed to examine its potential 
function(s) in KC biology. 
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Figure 1.1 
 
 
Figure 1.1. Illustration of the skin. The general structure of the skin is shown, 
including the thick dermal layer and the thin epidermis. Part of the subcutaneous 
layer is also show. The related structures are also illustrated. Original image from 
(1). 
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Figure 1.2 
 
 
Figure 1.2. Illustration of the epidermis and its keratinocyte layers. 
Keratinocyte proliferation begins at the basal layer (stratum basale) where new 
cells can begin to move out of is layer to differentiate. The process of 
cornification is shown as the cells transition to become the cornified layer 
(stratum corneum). Original image from (4). 
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TNFα-induced protein 3-interacting protein 1 (TNIP1) 
TNIP1 is a corepressor of PPARs and RARs 
Prior work in our laboratory discovered TNIP1 (also known as ABIN-1, 
Naf1 and VAN) as a novel coregulator of ligand-bound PPARs and RARs (Fig 
1.3) (23, 24). The requirement for ligand presence for TNIP1-NR interaction 
suggested TNIP1 as a NR coactivator. Intriguingly, the effect of TNIP1 interaction 
with NRs resulted in repression of these receptors’ activities. TNIP1’s direct 
binding to PPARs and RARs is facilitated by specific amino acid motifs within the 
TNIP1 sequence. TNIP1 exhibits a strong subtype preference amongst PPARs (γ 
> β/δ >>> α) and RARs (α >> γ) (23, 24), however it does not interact with the 
PPAR and RAR heterodimer partner retinoid X receptor (RXR). Additionally, 
TNIP1 had no effect on the activities of other NRs, such as estrogen receptors α 
and β, androgen receptor, and progesterone receptor (Encarnacao and 
Aneskievich, unpublished). The decrease in PPAR and RAR activity was not due 
to a reduction in NR expression levels, (23-25) supporting the interpretation that 
the repressive effect was due to TNIP1 alterating NR transcriptional activity. 
As a NR coregulator, TNIP1 is in a still relatively small class of 
corepressors of agonist-bound NRs exemplified by this group’s archetype, 
receptor interacting protein 140 (RIP140) (26). Unlike RIP140 (27), we found no 
association between TNIP1 and chromatin remodeling histone deacetylase 
(HDAC) enzymes. Rather, TNIP1 attenuates receptor activity acting through a 
different mechanism to halt excessive receptor activation either by toxic ligand 
levels or exposure to the ligand at inappropriate times. Additionally, even under 
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normal ligand conditions, coregulators may contribute to a combinatorial 
approach to NR regulation, providing for a finer level of control over receptor 
activity instead of the all-on or all-off effect of typical coactivators or 
corepressors. Furthermore, TNIP1 repression is partially relieved by over-
expression of the NR coactivator steroid receptor coactivator 1 (SRC1) 
suggesting that interference with coactivator recruitment by liganded NRs is a 
mechanism of TNIP1 repression (23). 
 The repressive effect observed on NRs indicates TNIP1 could play key 
roles in regulating KC proliferation and differentiation. Since ligand activation of 
PPAR and RAR results in changes KC cornification, altered TNIP1 expression 
could lead to significant changes in KC differentiation.  
 
TNIP1 blocks TNFα Receptor induced NF-κB activation  
Increased TNIP1 expression levels have also led to decreased activation 
of NF-κB via the TNFR (Fig 1.3). TNIP1 over-expression inhibits NF-κB signaling 
downstream of TRAF2 at the level of IKK, specifically NEMO. There is a direct 
physical interaction (28) between TNIP1 and NEMO (in addition to TNIP1 and 
A20). When TNIP1 levels are experimentally increased, A20-mediated removal 
of ubiquitin from NEMO is likely facilitated, decreasing the activity of the IKK 
complex, blocking NF-κB gene regulation (28, 29).  
 In addition to the interaction with NEMO, TNIP1 can also prevent NF-κB 
activation through decreasing the pool of one of the NF-κB subunits -- p50 (Fig 
1.3). NF-κB is a homo- or hetero-dimeric transcription factor consisting of 
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proteins in the Rel family. The p50 and p65 complex is the most common NF-κB 
dimer, with the p50 subunit derived from proteolytic processing of the precursor, 
and IκB protein, p105. Endogenous (30) and overexpressed (31) TNIP1 was 
found to bind and inhibit the processing of p105 resulting in a reduction of active 
p50. While the two proteins can physically interact, this is not an absolute 
requirement for the effect on p105. Interestingly, for any effect TNIP1 may have 
on intracellular signaling, increases in p105 expression significantly increased 
TNIP1 half-life (31). This protein-protein interaction could prevent NF-κB 
activation in two ways: (1)decreasing available p50 to form an active NF-κB 
dimer and (2)increasing TNIP1 expression to prevent IKK activation.  
 Further upstream of NEMO or Complex II, TNIP1 was found to interact 
with the TNFR. Haas and colleagues identified the various intracellular proteins 
recruited post TNFR ligand binding, including the IKK trimeric complex and 
TNIP1 (32). Although the specific details of how TNIP1 associates with the 
complex were not elucidated, mechanisms of NEMO’s association in this 
complex were discussed. NEMO’s ubiquitin binding domain, UBAN, facilitates the 
recruitment of the complex to other ubuquitinated TNFR bound proteins, such as 
RIP1 and TNFR-associated factor 2 (TRAF2). Given that TNIP1 also has the 
same UBAN domain, it is likely that its presence in the TNFR complex is 
mediated through TNIP1’s ability to bind ubiquitin chains.   
 
Implication for TNIP1 at the genetic level  
Current connections between TNIP1 and human pathologies are found in 
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several diseases and tissues including psoriasis, a chronic inflammatory skin 
disease. These associations derive from high throughput approaches such as 
genome-wide association studies (GWAS) and expression microarrays (33-39) 
(Table 1.1). Whether through sequence variations or expression levels, these 
approaches have linked TNIP1 with psoriasis, systemic lupus erythematosus 
(SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA) and 
leukemia/lymphoma. Additionally, the inflammation-associated defects observed 
using both in vitro and in vivo experimental systems are consistent with current 
reports of TNIP1 alterations associated with human auto-immune and chronic 
inflammatory diseases (Table 1.2). TNIP1’s wide tissue distribution (24, 25, 40) 
and involvement in a number of receptor-mediated signaling pathways (41) 
would likely extend impact of its altered function to non-immune cells. For 
instance, we found TNIP1 antibody staining in both stratified cutaneous and 
mucosal epithelial cells and germinal centers of human tonsil (25). More clearly 
defined roles for TNIP1 in normo- and patho-physiology will benefit from organ- 
and cell-specific knockout systems.   
 The TNIP1 gene has been implicated in psoriasis, SLE and SSc through 
at least three independent GWAS reports. In each case however, the strongest 
disease-associated single nucleotide polymorphisms (SNP) were in non-coding 
regions. In the psoriasis study (34), despite strong association with the disease 
(P-value 1 x 10-20) and ~1.5 fold increase in TNIP1 expression between lesioned 
and uninvolved skin (i.e., tissues from the same individual), the SNP was several 
kilobases upstream from the TNIP1 locus, indicating the TNIP1 promoter 
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sequence may be altered, possibly affecting TNIP1 expression.  
Similar to psoriasis, SNPs in non-coding TNIP1 regions were also disease 
associated with SSc. Three different TNIP1 SNPs were identified in European 
populations in the second GWAS report for SSc (39). Intriguingly, when TNIP1 
mRNA and protein levels were assessed from cultured dermal fibroblasts of SSc 
patients, a ~1.7-fold decrease was observed. A separate GWAS study also 
identified SNPs in SLE. Two TNIP1 intronic SNP variants were found in SLE 
patients from Chinese Han, Caucasian, and Japanese populations, with the latter 
two groups having the same SNP (35, 36, 38). Unlike the altered expression of 
TNIP1 in psoriasis and SSc, there was no TNIP1 mRNA change associated with 
this SLE SNP (38). However, Kawasaki and colleagues suggested the SNP 
location in intron 1 could impact TNIP1 splicing possibly affecting the use of 
alternative exons 1A and B with exon 2 and thereby contributing to the numerous 
splice variants of TNIP1 (42-44) with as yet unrecognized consequences. Far 
from being innocuous spacers between coding regions of genes, introns are now 
recognized as possible sites of transcription-regulating factors at the DNA level 
and/or potential effectors of splicing at the RNA level (45, 46). Likewise, proximal 
or intergenic regions, especially those covering the disease-associated gene’s 
promoter/enhancer region, may affect expression levels or tissue-specific 
expression (47). Most recently, copy number variations were reported for 
TNFΑIP3 and TNIP1 suggesting other forms of genome-wide analyses could 
prove productive in relating these genes to the disease states (48).  
 Through physical association with TNFR pathway, the molecular 
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mechanisms of TNIP1’s function to inhibit NF-κB-dependent gene transcription 
may explain its potential role in inflammatory and immune-related diseases. 
Deregulation of this pathway can result in a myriad of diseases and disorders, 
including but not limited to the progression of arthritis and psoriasis, and yet, 
controlled TNFR signaling can lead to differentiation and immunomodulation in 
equally diverse cell types (49, 50). As previously mentioned for leukemia-
lymphoma (43, 51) and psoriasis (34, 52), TNIP1 association with disease states 
need not be limited to variants in its protein sequence. Wild-type TNIP1 could still 
play a key role in pathologies or as a pharmacologic target if its levels were 
altered.  
 
TNIP1 sequence variants at the mRNA and protein level 
 In addition to gene analysis, TNIP1 mRNA expression has been analyzed 
from several human cell lines and tissues. Several splice variants having either 5’ 
truncated ends or lacking specific exons were detected in samples derived from 
patients with acute myeloid leukemia (AML) (43). Although variant 5’ ends have 
been mapped to the use of alternative first exons, the 3’ truncations described in 
these samples are the first of their kind to be reported. Most of the splice variants 
did not confer changes in amino acid sequence. However, one variant lacking 
exons 16 and 17 was less effective at reducing NF-κB activity. Decreased TNIP1 
mRNA levels, for with full-length or splice variants, were observed in AML patient 
samples post chemotherapy treatments. Separately, several TNIP1 mutations 
have been detected in gastrointestinal diffuse large B cell lymphomas (51). 
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These sequence alterations are either point or frame-shift mutations, the latter 
resulting in a protein truncation. One mutant in particular, causing a glutamic acid 
to lysine change (E476K), lost its NF-κB inhibitory properties; other missense 
mutations did not alter this TNIP1 property. Thus, sequence variations, either at 
the mRNA level possibly affecting message stability, exon content, or amino acid 
sequence could impact ultimate TNIP1 protein function. Additionally, we should 
consider that there could be functional consequence to even wild-type TNIP1 
protein if its levels or post-translation processing, e.g. phosphorylation were 
altered. 
 
Increased expression of TNIP1  
 In contrast to other TNIP1 associated diseases, the connection between 
TNIP1 and RA appears strictly at the expression level, not at a susceptibility 
locus or nucleotide mutation. Three SNP type GWAS reports (38, 53, 54) 
concluded loci-disease association(s) did not meet the cut-offs used for the 
analyses. However, when compared to knee synovial membrane biopsies from 
osteoarthritis patients, similar samples from patients with RA showed a 2.5-3.5 
fold TNIP1 mRNA increase. Osteoarthritis and RA are referred to as non-
inflammatory versus inflammatory forms of the disease, respectively. Consistent 
with this inflammatory association, TNIP1 was one of the genes with increased 
expression following TNFα treatment of cultured synovial fibroblasts (33). 
Nevertheless, TNFα-increased TNIP1 expression may be tissue specific by 
following one of multiple post-TNFα-receptor signaling pathways. For instance, 
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retrovirus-mediated increases in NF-κB signaling, one of several post-TNFα-
receptor consequences, did not increase TNIP1 expression in dermal fibroblasts 
but did in epidermal keratinocytes (55). TNIP1 upregulation in response to 
signaling from inflammatory mediators coupled with dampening of NF-κB activity, 
at least in experimental systems, suggests its dysregulation may be contributory 
and/or consequential to cytokine signaling.  
 
Non-coding changes in TNIP1 and possible connections to disease  
The quandary of how TNIP1 non-coding region SNPs affect psoriasis, 
SLE and SSc is much the same as for any other extra-exonic sequence changes 
associated with disease. Sequence alterations in promoter regions, even those 
distant to transcription start sites may affect transcription factor binding and, in 
turn, mRNA production. Likewise, SNPs in non-coding regions may alter 
transcript conformation resulting in changes in its stability, translational efficiency, 
or interaction with RNA regulatory factors (56). Thus even the wild-type TNIP1 
protein sequence at altered levels could impact the associated disease states 
given the ability of TNIP1 to modulate post-receptor signaling as detailed below. 
In the case of RA, experiments using fibroblast-like synoviocytes show wild-type 
TNIP1 increases pro-inflammatory cytokines, potentially advancing the disease 
(57). In this vein, as psoriasis, SLE, and RA are at least in part regulated (58) by 
receptor pathways (TNFR) modulated by TNIP1, TNIP1 itself could be a focal 
point for clinical intervention. This possibility is again echoed by TNIP1 
corepression of nuclear receptors currently used as therapeutic targets (RAR) 
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(59) or suggested for such use (PPAR) (60, 61) for treatment of psoriasis or other 
inflammatory diseases (62). However, a discrepancy arises in TNIP1’s inhibitory 
effect on TNFR signaling and increasing pro-inflammatory cytokines in RA. We 
hypothesize that TNIP1 could regulate these molecules through a separate 
pathway distinct from TNFR (57). Therefore, while several targets have been 
elucidated, it is plausible that other TNIP1-mediated pathways have not yet been 
discovered. 
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Figure 1.3 
 
 
Figure 1.2. TNIP1-mediated signaling pathways. (Left) In the TNFR-induced 
NF-κB activation pathway, intracellular proteins are recruited to the TNFR to form 
complex I, which facilitates the phosphorylation and subsequent activation and 
polyubiquitination of NEMO. IB is then targeted for degradation, allowing the 
p65/p50 NF-ΚB heterodimer to translocate into the nucleus. TNIP1 inhibits NF-
ΚB activation by preventing NEMO’s polyubiquitination. Additionally, TNIP1 
blocks the processing of p105 to the NF-ΚB subunit p50, therefore decreasing 
the available pool of NF-ΚB. (Right) TNIP1 represses nuclear receptors 
transcriptional activity. Upon ligand-NR binding, TNIP1 exerts its inhibitory effects 
on either PPAR or RAR. Red (ᴓ) denotes TNIP1’s inhibitory functions.  
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Table 1.1. TNIP1 and associated diseases 
Disease 
TNIP1 
Association 
Experimental 
Approach 
Reference 
Psoriasis 
Intronic SNP; 
Increased 
expression 
GWAS; Gene 
expression 
microarray 
Nair et al. (34); Psoriasis 
Consortium (52); Ellinghaus 
et al. (63) 
Psoriatic Arthritis Intronic SNP GWAS Bowes et al.(64) 
Systemic Lupus 
Erythematosus 
Intronic SNP GWAS Kawasaki et al. (38) 
Systemic 
Sclerosis 
Intronic SNP GWAS Allanore et al. (39) 
Leukemia-
Lymphoma 
Splice Variants 
RT-PCR and 
sequencing 
Shiote et al. (43) 
Leukemia-
Lymphoma 
Point or frameshift 
mutations 
PCR and 
sequencing 
Dong et al. (51) 
Rheumatoid 
Arthritis 
Increased 
expression 
Gene Expression 
microarray 
Gallagher et al. (33) 
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Table 1.2. Experimentally altered TNIP1 and the resulting phenotypes 
Experimental Model Phenotype Reference 
Overexpression of WT TNIP1 
in vivo via adenoviral tail vein 
delivery  
Protection from 
TNFα/Galactosamine induced acute 
liver failure 
El Bakkouri et al. (65) 
Overexpression of WT TNIP1 
in vivo via adenoviral 
intratracheal delivery 
Protection from allergen induced 
airway inflammation 
Wullaert et al. (66) 
Mouse knockout by BAC 
recombineering and Cre 
mediated excision to delete 
sequences including exons 12-
15 
1 in 40 mice were live-born; 
Embryonic lethal at day 18.5; 
Anemic; Hypocellular livers; 
Increased apoptosis in embryonic 
livers 
Oshima et al. (67) 
Gene trap mutation mouse 
model 
1 in 40 mice were live-born; 
Embryonic lethal at day 18.5; Live-
born mice die within 40 days post-
birth; Enlarged lymph nodes and 
spleen 
Zhou et al. (68) 
Mouse knock-in model 
mutating TNIP1’s UBAN 
domain 
Development of lupus-like 
autoimmune disease within 5 
months; Enlarged lymph nodes and 
spleen;  
Nanda et al. (69) 
Overexpression of WT TNIP1 
in vitro in Saos-2 
osteosarcoma cells 
Protection from trichostatin A 
induced apoptosis 
Zhang et al. (70) 
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Heat shock proteins 
Heat shock proteins and the skin 
Epidermal KCs serve as the primary barrier between the numerous 
environmental chemicals and toxins and the body (71). These cells are likely to 
respond through a number of mechanisms and proteins to protect them from 
toxicity or death. Heat shock proteins (HSP) are a superfamily of molecules 
involved in protecting cells from numerous stress events. Initially discovered in 
Drosophila after incubating in increased temperatures (72), increase HSP 
expression was observed in response to toxic chemical and UV light assaults 
across all cell types and organisms (71). HSPs were reported to refold of 
denatured proteins and block protein aggregation, therefore preventing cell 
death. However, further characterization of many HSPs revealed constitutive 
expression of several family members. These constitutively expressed HSPs 
account for their availability in “house-keeping” chaperone function (73).  
Different HSP subfamilies, which are classified according to their 
molecular weight (73), are found in the skin. The HSPA family (also named 
HSP70) has been well studied in KC biology. Members of this family are 
observed in both unstressed and stressed KCs (74, 75). Several family members 
have mostly similar with some distinct functions in the cell with regards to the 
proteins they can interact with and fold. HSPA1A (HSP70) is the best known 
HSPA family member. This protein is expressed in KCs, but can still be highly 
stress induced. The HSPA1A chaperone function is vital in unstressed 
conditions, while its expression in stress-induced cells is crucial to prevent cell 
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death. Targeting HSPA1A to reduce its expression using an antisense oligomer 
induced cell death and inhibited cell growth (76). A closely related family 
member, HSPA6 (HSP70B’) expression is also observed in both conditions. 
While these two proteins are key to cell protection in stressed conditions, each 
can bind specific proteins with higher affinity than others. For example, HSPA6 is 
more effective at binding and refolding p53, whereas it does not interact with 
HSPA1A-specific protein substrates from the peroxisome (77, 78). However, both 
proteins are important to normal cell homeostasis because specific knockdown of 
either HSP resulted in reduced cell survival following thermal or chemical stress. 
Furthermore, decreasing the expression of both HSPs led to a greater reduction 
in cell survival, suggesting both are important in cell protection (79). Additionally, 
increased expression of HSPA1A led to enhanced cell growth and proliferation, 
suggesting it may regulate this process. In KC specific tissues, increased 
expression of several HSPs, including HSPA1A, was observed in psoriatic 
lesions (80). While the exact function of HSPs in psoriasis is yet unknown, it is 
speculated that the increased expression could be a result of inflammation within 
the keratinocytes. Regardless, this observation could indicate a functional role for 
HSPs in the pathogenesis of inflammation. 
 
Expression and transcriptional regulation of heat shock protein A6 
The expression of HSPA6 is less characterized and understood compared 
to other HSPs. HSPA6 mRNA and protein expression is highly induced following 
either thermal, chemical or UV stress in all cells examined (81, 82). In non-
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stressed conditions, HSPA6 production is variable, from none detected to low 
expression levels (79, 81, 82). This could possibly be dependent on cell type and 
growth condition differences (83). Currently, the transcriptional regulation of 
HSPA6 has mostly been characterized using a minimal ~287 bp promoter (84-
86). To date, a functional activator protein 1 (AP1) site and heat shock response 
element (HSE) have been characterized. Additionally, a predicted TATA box was 
found, but not yet analyzed. Initial work from our laboratory observed high 
expression levels of HSPA6 in basal, unstressed conditions. This level was 
further increased in response to thermal stress (Ramirez et al 2014, submitted). 
These findings may indicate HSPA6, like HSPA1A, plays key roles in normal, 
stressed and diseased KCs to possibly modulate the pathogenesis of skin related 
diseases. 
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Summary 
 Proper regulation of epidermal KC homeostasis is essential to generate a 
functional barrier to separate the possible environmental stressors from our body. 
Outlined in this chapter are only some of the proteins involved in regulating the 
proliferation and differentiation of KCs in both normal and diseased states. We, 
and others, characterized TNIP1 as one of those possible factors. TNIP1 can 
directly or indirectly repress the activity or activation of transcription factors 
involved in KC proliferation and differentiation. Sequence alterations and 
expression level changes were observed in several inflammatory diseases, 
including those affecting KC growth. However, TNIP1’s exact role in these 
diseases are not yet understood. In the research presented on this dissertation, 
we sought to characterize the transcriptional and cellular outcomes of increased 
TNIP1 expression in human KCs to possibly contribute in understanding TNIP1’s 
role in normal or diseased skin.   
Using a gene microarray analysis to examine the transcriptional 
expression changes in TNIP1-overexpressing cultured KCs, this research 
validated TNIP1’s role in the previously mentioned associated inflammatory 
diseases. Expression of TNFR- and NR-regulated genes was also reduced 
following increased TNIP1 exposure, confirming TNIP1’s repressive effect on 
these pathways. Interestingly, we observed the novel repression of genes 
associated in regulating the cell stress response, HSPs. Choosing one HSP 
(HSPA6), we examined the potential mechanism of how TNIP1 could repress a 
family HSPs. We determined that the transcriptional repression of HSPA6 is not 
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through previously characterized TNIP1 factors, suggesting TNIP1 could regulate 
a yet uncharacterized pathway. In addition to the possible transcriptional 
changes involved with TNIP1, we assessed the overall cellular consequence of 
increased TNIP1 levels. This work suggests that a chronic, but not acute, 
overexpression of TNIP1 results in reduced growth of cultured KCs. These 
results indicate that TNIP1 could regulate KC growth and differentiation, possibly 
through repression of HSP expression. 
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Chapter 2 
TNIP1 Modulates Heat Shock Protein Expression and the Stress Response 
Abstract 
A vast number of cellular responses to environmental and physiological 
signals are regulated by various receptor-initiated pathways, which in turn are 
modulated by a diverse set of regulatory proteins. TNFα-induced protein 3-
interacting protein 1 (TNIP1) is one such protein; it inhibits both transduction by 
transmembrane receptors, such as the TNFα-receptor, and by nuclear receptors 
PPAR and RAR activity. Despite their cytoplasmic versus nuclear signaling, 
these receptors play key roles in regulating inflammation and inflammatory 
diseases. Interestingly, a growing number of references through GWAS and 
expression studies have implicated TNIP1 in chronic inflammatory diseases such 
as psoriasis and rheumatoid arthritis. However, TNIP1’s exact role has yet been 
determined.  
To characterize the specific genes and pathways affected by TNIP1, we 
overexpressed TNIP1 in HaCaT keratinocytes. Using a gene microarray analysis, 
we observed reduced expression of most genes altered. These results not only 
validated previously determined TNIP1-repressed pathways and biological 
processes, but also revealed novel TNIP1-affected pathways, such as the cell 
stress response. Specific proteins involved in this process, heat shock proteins 
(HSP), showed reduced mRNA and protein expression following increased 
TNIP1 levels. When TNIP1 levels were increased in normal human epidermal 
keratinocytes, the repression of HSPs were only observed in differentiating 
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keratinocytes. Additionally the induction of one keratinocyte differentiation 
marker, involucrin, was blocked by TNIP1. This may indicate that keratinocyte 
differentiation may be slowed by increased levels of TNIP1. Keratinocytes rely on 
HSPs for both chaperone and stress recovery functions, during differentiation 
and inflammation. Their reduced expression by TNIP1 could compromise cell 
function, possibly affecting KC homeostasis.  
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Introduction 
 TNF-induced protein 3-interacting protein 1 (TNIP1) is an intracellular 
regulatory protein that blocks or represses various signaling pathways involved in 
normal cell physiology and the pathogenesis of several inflammatory diseases, 
such as psoriasis, systemic lupus erythematosus and rheumatoid arthritis (34, 
38, 87). These pathologies share a hyper inflammatory nature, in part, resulting 
from dysregulation of a diverse group of receptor-mediated signaling pathways, 
possibly involving altered TNIP1 levels or functions. For instance, increased 
levels of TNIP1 were observed in skin samples from patients with psoriasis, a 
chronic inflammatory disease characterized by keratinocyte (KC) hyper-
proliferation and incomplete differentiation. Research from our laboratory 
determined TNIP1 as a ligand-dependent nuclear receptor corepressor, 
specifically of peroxisome proliferator activated receptor (PPAR) and retinoic acid 
receptor (RAR) (23, 24). Work from other laboratories characterized TNIP1 
blocking transmembrane receptor-initiated cascades, such as TNF receptor 
(TNFR) (28, 31, 88), epidermal growth factor receptor (EGFR) (89), and toll-like 
receptor (TLR) (69, 90), resulting in the reduced activation of NF-κB, Elk-2 and 
C/EBPβ, respectively. Overall, TNIP1 can be classified as a direct or indirect 
repressor of transcription factor activation or activity (for a recent review on 
TNIP1, refer to (41)). Although TNIP1’s association in these cascades and 
diseases has been observed, the consequences and specific genes affected by 
increased TNIP1 have not yet been established. To assess the role TNIP1 plays 
in KC biology, we performed a gene microarray using samples from TNIP1-
 28 
overexpressing cultured KCs. The gene clustering analysis not only confirmed 
TNIP1’s association in known inflammatory diseases and processes, but it also 
found a novel pathway involved in TNIP1 signaling — the cell stress response 
centering on heat shock proteins (HSP). 
HSPs are molecular chaperones initially discovered (72) for their 
protective roles during cellular stress by preventing protein unfolding and 
aggregation (71, 73). Under basal, unstressed conditions, these proteins aid in 
new protein folding and shuttling. Similar to other cell types, epidermal 
keratinocytes have basal and stress inducible levels of HSPs (74, 80, 91). 
Because the keratinocytes are a first line barrier between various environmental 
stressors and the body, HSPs are key to protecting keratinocytes from the 
damage caused by cellular stressors, including UV exposure, chemical treatment 
or increased thermal changes (71). 
The HSPA (also named HSP70) family is well known and widely studied in 
skin biology. In unstressed skin, HSPA1A, the best-characterized member of this 
family, is primarily found in the major cell type in the epidermis, KCs, but not 
other cell types, such as melanocytes and fibroblasts (92). Pharmacologic 
repression of HSPA1A expression in keratinocytes resulted in reduced resistance 
to UV treatment (93). Further, increased expression of HSPA1A is observed in 
psoriatic lesions (80) and wound healing (94), suggesting a potential role for 
these chaperones in these pathologies. The expression of a close relative of 
HSPA1A, HSPA6 (also named HSP70B’), has recently been established in KCs 
(74). This protein has some similar protective functions compared to HSPA1A 
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(79) although each has distinct protein substrates as examined through protein 
binding with endogenous or experimentally expressed proteins. HSPA6 has 
preferential binding to unfolded p53, but has no effect on HSPA1A protein 
subtrates, luciferase enzyme and peroxisomal proteins (77, 78). It is speculated 
that HSPA6 may act as a backup response to stressors, whereas HSPA1A is the 
primary response. Regardless, siRNA-mediated knockdown of either HSP 
resulted in decreased cell survival post thermal and chemical stress, indicating 
both HSPs are crucial for cell protection (79).  
In this chapter, we examined the cell signaling effects and gene 
transcriptional changes due to overexpression of recombinant TNIP1. Although 
TNIP1 was previously shown to block pathways initiated by nuclear and 
transmembrane receptors (23, 24, 28, 31, 88), this repression was assessed 
using reporter gene constructs, not through quantifying the expression of 
endogenous target genes. To determine the specific genes, we performed a 
gene microarray analysis of TNIP1-overexpressed HaCaT KCs to confirm the 
biological functions and pathways associated with TNIP1, as well as to search for 
novel pathways altered by TNIP1. In addition to affecting pathways involved in 
inflammation and cell death, increased TNIP1 affected a not yet characterized 
TNIP1-associated pathway, regulation of the stress response. We observed 
reduced levels of several heat shock proteins (HSP), including HSPA1A and 
HSPA6. These results could suggest a novel TNIP1 function in modulating the 
cell stress response.   
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Materials and Methods 
Cell Culture  
HaCaT KCs (95) were cultured in 37C with 5% CO2 humidified incubator 
in a 3:1 DMEM/F12 media containing 10% FBS (Thermo Scientific HyClone, 
Logan, UT), 100U/ml penicillin, and 100 mg/ml streptomycin. The cells were 
plated on 6- or 24-well plates at a density of 6.8 x 105 or 1.5 x 105 cells per well, 
respectively. Twenty-four hours after, cells were infected with an adenovirus 
construct expressing TNIP1 (Ad-TNIP1) or LacZ as a control (Ad-LacZ) at an 
multiplicity of infection (MOI) of 500 using Polybrene infection reagent (Millipore, 
Billerica, MA) (96). Sixteen hours post-infection, the viral mixture was aspirated 
and media replaced. Twenty-four hours post-infection, cells were collected for 
total RNA using the RNeasy kit (Qiagen, Valencia, CA) or protein using RIPA 
lysis buffer (10 mM Tris, 150 mM NaCl, 1% deoxycholic acid, 1% Triton, 0.1% 
SDS).  
Normal human epidermal keratinocytes (NHEK) were cultured in 37C 
with 5% CO2 humidified incubator in a KBM-Gold supplemented with KBM-Gold 
Bullet Kit (Lonza Biologics Inc, Hopkinton, MA) at passage number 2-4. Cells 
were plated on 6-well plates at 9.5 x 104 cells per well. Forty-eight hours after, 
cells to be collected from low calcium (0.1 mM) media were infected with Ad-
TNIP1 or Ad-LacZ (control) at an MOI of 50 (assuming one cell doubling time has 
occurred)using Polybrene infection reagent. Twenty-four hours after infection, the 
cells cultured in low calcium medium were collected for total RNA using the 
RNeasy kit (Qiagen) or protein using RIPA lysis buffer, while the media for the 
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the cells grown in high calcium was replaced with fresh media supplemented to a 
final concentration of 1.2 mM calcium. Forty-eight hours after, high calcium 
cultured cells were infected with Ad-TNIP1 or Ad-LacZ (control) at an MOI of 50 
(assuming a total of 4 cell doubling times have occurred) using Polybrene 
infection reagent. Twenty-four hours after infection, the cells cultured in high 
calcium medium were collected for total RNA using the RNeasy kit (Qiagen) or 
protein using RIPA lysis buffer.  
  
Microarray 
Total RNA isolated from LacZ- or TNIP1-expressing adenovirus infected 
cells was provided to the University of Connecticut Health Center Molecular Core 
Facility for microarray analysis. The microarray was performed using the Illumina 
Human WG-6 3.0 Expression Bead Chip and analyzed using the GenomeStudio 
software (Illumina, San Diego, CA). Significantly altered genes were determined 
using a fold change of ≥ 2 and a p-value ≤ 0.05 (DiffScore = 13). Functional 
grouping and analysis was performed using Ingenuity Pathway Analysis online 
software (Ingenuity Systems, www.ingenuity.com) and the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) web-accessible 
program (97, 98).  
 
Real-Time quantitative PCR analysis 
Reverse transcription was performed using aliquots from the total RNA used for 
the microarray using the iScript reverse transcriptase (BioRad, Hercules, CA). 
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Gene expression changes were analyzed using POWER SYBR green master 
mix (Life Technologies, Grand Island, NY). Real-time PCR was performed using 
Applied Biosystems 7500 Fast Real-Time PCR system. Data analysis was 
carried out on ABI 7500 software using the ΔΔCT method. The primer sequences 
used and reaction conditions are listed on Table 2.1. All data was normalized to 
the ribosomal proten L13a (RPL13a) (99).  
 
Immunoblot analysis 
Whole-cell lysates were prepared in RIPA buffer and the protein concentration 
was determined using the 660 nm Protein Assay (Thermo Pierce). Ten 
micrograms of protein were separated by SDS/PAGE, transferred to 
nitrocellulose membranes, rinsed with nanopure water and treated with Qentix 
(Thermo Scientific Pierce). Blots were incubated in blocking buffer consisting of 
5% (w/v) non-fat dried milk, phosphate-buffered saline, and 0.1% Tween 20, then 
probed with HSP70B’ antibody (ADI-SPA-754) at 1:1000 dilution (Enzo Life 
Sciences, Farmingdale, NY) or anti-HSPA1A antibody (ADI-SPA-810) at 1:1000 
dilution (Enzo Life Sciences) (82, 83) followed by HRP (horseradish peroxidase)-
conjugated secondary goat anti-mouse antibody at 1:10,000 dilution 
(PerkinElmer, Branford, CT). Blots were subsequently probed with -actin 
antibody (ab8227) at 1:5,000 dilution (Abcam, Cambridge, MA) followed by HRP-
conjugated secondary goat anti-rabbit antibody at 1:20,000 dilution 
(PerkinElmer). Between probing steps, blots were washed with 0.2% Tween20 in 
phosphate-buffered saline. Detection of binding was determined with enhanced 
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chemiluminescence reagents (Thermo Scientific Pierce). Band signals were 
digitally captured and analyzed using the Kodak image station CCF and 
Carestream molecular imaging software. 
 
Statistical Analysis 
Data was analyzed using Prism Software version 5 (GraphPad) (La Jolla, CA). 
Student’s T-test was use to compare between pairs. Statistical significance was 
defined as p  0.05.  
 
  
 34 
Table 2.1 List of qPCR primers 
Primer name Primer sequence 5’ to 3’ 
HSPA6, forward CTC CAG CAT CCG ACA AGA AGC 
HSPA6, reverse ACG GTG TTG TGG GGG TTC AGG 
IL6, forward GGT ACA TCC TCG ACG GCA TCT 
IL6, reverse GTG CCT CTT TGC TGC TTT CAC 
DNAJB1, forward GAG GAA GGC CTA AAG GGG AGT 
DNAJB1, reverse AGC CAG AGA ATG GGT CAT CAA 
HSPA1A, forward AGG TGC AGG TGA GCT ACA AG 
HSPA1A, reverse ATG ATC CGC AGC ACG TTG AG 
RARRES3, forward CAA GAG CCC AAA CCT GGA G 
RARRES3, reverse TAT ACA GGG CCC AGT GCT CAT 
NFKBIA, forward AAC CTG CAG CAG ACT CCA CT 
NFKBIA, reverse ACA CCA GGT CAG GAT TTT GC 
DNAJA1, forward TCA AAC CCA ATG CTA CTC AGG A 
DNAJA1, reverse TCC ACC CTC TTT AAT TGC CTG T 
RNASE7, forward GGA GTC ACA GCA CGA AGA CCA 
RNASE7, reverse CAT GGC TGA GTT GCA TGC TTG A 
MAKP13, forward TGC TCG GCC ATC GAC AA 
MAKP13, reverse TGG CGA AGA TCT CGG ACT GA 
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Results 
TNIP1 overexpression analysis using a gene microarray  
To determine the effect of increased TNIP1 levels in keratinocytes (KC), 
recombinant TNIP1 was overexpressed in HaCaT KC, a human immortalized, 
but non-tumorigenic KC cell line which retains the KC differentiation properties 
(95). Using an adenoviral vector expressing either TNIP1 (Ad-TNIP1) or control 
gene LacZ (Ad-LacZ) at a MOI=500, a ~11-fold increase of TNIP1 protein was 
observed twenty-four hours after adenoviral infection (Fig 2.1). Increased 
expression of TNIP1 was further examined at 48, 72 and 96 hours post-infection. 
Expression of TNIP1 did not change throughout these later timepoints (data not 
shown). The mRNA changes at 24 hours post-infection was chosen for the 
microarray to reduce the chances of gene expression changes due to further 
downstream protein expression changes. 
 
Increased TNIP1 results in repression of a majority of genes  
To assess the possible direct repressive effect on TNIP1 on target genes’ 
transcription, we extracted total RNA lysates from the Ad-LacZ and Ad-TNIP1 
infected cells twenty-four hours post-infection for a gene microarray analysis. 
Using the Illumina whole genome expression array, we observed 139 
significantly regulated genes using cutoffs of 2-fold and a p-value  0.05. We 
plotted these results and observed that 136 genes’ expression was reduced, 
while only 3 genes were increased (Fig 2.2, top panel). The volcano plot shows 
log2-fold change in mRNA expression between the control and TNIP1- 
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Figure 2.1  
 
 
Figure 2.1. Validation of TNIP1 overexpression. Expression and quantitation 
of TNIP1 protein in control (Ad-LacZ) or TNIP1-overexpressed (Ad-TNIP1) 
HaCaT KCs. Statistical significance was determined using Student’s t-test, ** p < 
0.01. Bars are mean + SEM from experimental triplicates. 
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overexpressed samples on the x-axis and the negative log of the DiffScore 
(transformed p-value) on the y-axis. Each point on the plot represents a single 
gene.  
To validate the use of the microarray, we performed a qPCR analysis of 
selected genes. Genes which were maximally reduced (HSPA6 and IL-6) and 
increased (RNase7 and MAPK13) were among those chosen. Additionally, we 
chose previously determined nuclear receptor and NF-kB regulated genes 
(RARRES3 and NFKBIA, respectively) (Fig 2.2, bottom panel). A similar trend in 
gene reduction and induction was observed comparing the microarray and 
qPCR.  
 
Determining the biological functions and pathways affected by increased TNIP1 
 To determine the biological processes most relevant to our TNIP1 
overexpression microarray, we used two pathway analyses and clustering web-
accessible programs, Ingenuity Pathway Analysis (IPA) and the Database for 
Annotation, Visualization and Integrated Discovery (DAVID). The IPA analysis 
can group the significantly altered gene list by biological function and 
toxicological pathways affected. The top associated biological functions affected 
by increased TNIP1 levels include cancer, cell death, inflammatory diseases and 
gene expression (Fig 2.3, top panel). The IPA pathway clustering analysis 
showed that pathways involving PPAR and RAR activation were affected in the 
microarray (Fig 2.3, bottom panel). Further, pathways previously unknown to be 
regulated by TNIP1 were affected, especially stress associated pathways. 
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Figure 2.2  
 
 
 
Figure 2.2. TNIP1 overexpression microarray results. Top panel. Volcano plot 
analysis of microarray results. Each point represents one gene. Bottom panel. 
Validation of microarray using qPCR. Note break in axis and change in scale. 
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Figure 2.3  
 
 
 
Figure 2.3. Ingenuity Pathway Analysis clustering of genes with significant 
expression change. Top panel. IPA biological function analysis of the top 
affected clusters. Bottom panel. IPA pathway cluster of the top affected pathways 
above the threshold.   
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 To further confirm the pathways and functions observed using IPA, we 
also used the separate functional annotation software, DAVID. The top gene 
functional classifications observed were similar to the IPA clustering (Fig 2.4). 
From the DAVID analysis, the unexpected pathway affected by TNIP1 was the 
stress response pathway. To determine the potential TNIP1 effect on this novel 
TNIP1-associated pathway, we looked at the specific genes within this pathway 
altered by TNIP1.  
 
Heat shock response genes’ expression is repressed by TNIP1 
The microarray results showed reduced expression of five HSP family 
members (HSPA6, DNAJB1, HSPA1B, HSPA1A and DNAJA1) by 20-, 5-, 3.2-, 
3- and 2-fold, respectively. HSPA6 was the gene most repressed by TNIP1 in our 
analysis. Results from the microarray were validated via qPCR (Fig 2.5, top 
panel). Since the role of the HSPA family is better characterized in keratinocyte 
biology, we further assessed whether TNIP1’s inhibitory effect on these genes 
extend to altered protein expression. We observed reduced protein expression of 
both HSPA1A and HSPA6 in response to enhanced TNIP1 protein expression 
(Fig 2.5, bottom panel).  
In addition to using the HaCaT keratinocytes, we also examined the 
transcript expression levels of HSPA1A and HSPA6 in cultured normal human 
skin keratinocytes (NHEK). A well characterized and used method to induce 
NHEK differentiation from an undifferentiated population is to switch the media 
calcium concentration from low to high amounts. To test if the calcium switch 
 41 
induced KC differentiation, we examined the mRNA levels of two KC 
differentiation markers observed in the spinous and granular layers, keratin 1 and 
involucrin, respectively (Fig 2.6). Control infected cells show 38- and 13-fold 
increased expression of keratin 1 and involucrin, respectively, suggesting KC 
differentiation is occurring. Interestingly, HSPA1A and HSPA6 expression was 
increased in differentiating KC compared to the undifferentiated KC (Fig 2.7). The 
TNIP1-mediated repression of these genes was only observed in differentiating 
keratinocytes. TNIP1 had no effect on HSPA1A and HSPA6 in low calcium 
cultured cells.  
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Figure 2.4  
 
 
Figure 2.4. DAVID clustering of genes with significant expression change. 
DAVID biological function analysis of the top affected clusters.  
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Figure 2.5  
 
 
 
Figure 2.5. Effect of TNIP1 overexpression on HSPs in HaCaT KCs. Top 
panel. Microarray and qPCR analysis of HSPA6, DNAJB1, HSPA1A and 
DNAJA1 in HaCaT KCs. Bottom panel. Western blot analysis of HSPA1A and 
HSPA6 in HaCaT KCs. -actin is used as a loading control.  
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Figure 2.6  
 
 
Figure 2.6. Effect of TNIP1 overexpression on KC differentiation markers in 
NHEKs. Quantitative PCR analysis of keratin 1 (left graph) and involucrin (right 
graph) in undifferentiated (low calcium) or differentiated (high calcium) NHEKs 
infected with Ad-LacZ (control) or Ad-TNIP1. Statistical significance was 
determined using Student’s t-test, * p < 0.05. Bars are mean + SEM from 
experimental triplicates. 
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Figure 2.7  
 
 
Figure 2.7. Effect of TNIP1 overexpression on HSPs in NHEKs. Quantitative 
PCR analysis of HSPA1A (left graph) and HSPA6 (right graph) in undifferentiated 
(low calcium) or differentiated (high calcium) NHEKs infected with Ad-LacZ 
(control) or Ad-TNIP1. Statistical significance was determined using Student’s t-
test, * p < 0.05. Bars are mean + SEM from experimental triplicates. 
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Discussion 
 The expression and roles of TNIP1 in cells and tissues are still being 
determined. Through several genome wide association studies and gene 
expression analysis, TNIP1 has been linked to various inflammatory diseases 
(34, 38, 39, 87). Additionally, TNIP1’s repressive effects have been observed 
experimentally in several receptor-mediated pathways, including TNFR and 
nuclear receptors, using promoter-responsive reporter constructs (24, 25, 28, 31, 
69, 88) (refer to (41) for review). Consistent with TNIP1’s repression of these 
pathways, our microarray results using cells overexpressing TNIP1 resulted in 
reduced expression of 136 of 139 genes, validating TNIP1’s repressive effect. 
Decreased expression of TNFα and nuclear receptor target genes, including 
interleukin 6 (IL6), NFkB inhibitor alpha (NFKBIA) and retinoic acid receptor 
responder 3 (RARRES3), were observed, confirming TNIP1’s role in repressing 
these pathways.  
Pathway clustering analysis showed functions related to cancer, cell death 
and immunological diseases were affected using IPA, while DAVID (97, 98) 
analysis showed functions related to antiviral defense, transcription and cell 
death. The classification for cancer, immunological diseases and antiviral 
defense could be related because each of these functions have similar altered 
genes that are associated with inflammation. The specific functional grouping 
could be annotated differently within these clustering programs. However, since 
the gene lists altered are the similar, this could make the association between 
TNIP1 and these pathways stronger. A previously unknown TNIP1-associated 
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function affected from the TNIP1 overexpression in HaCaT KCs was the stress 
response pathway, indicating TNIP1 could play a role in modulating the cell 
stress response in skin KCs.  
Expression levels of several stress-responsive genes from two HSP 
families, HSPA and DNAJ (also named HSP70 and HSP40, respectively), were 
decreased after TNIP1 overexpression in HaCaT KCs. HSPA1A/B, HSPA6, 
DNAJA1, and DNAJB1 levels were reduced as much as 20-fold in the 
microarray. In addition to their key roles in protecting the cell from various 
stressors, they play equally important functions in unstressed cells as molecular 
chaperones. Protein expression analysis for HSPA1A and HSPA6 further 
showed reduced protein expression, suggesting HaCaT KCs may have a 
reduced capacity to tolerate exposure to cell stressors with increased TNIP1 
levels. In unstressed cells, TNIP1 could affect new protein synthesis and 
shuttling through reduced expression of HSPs, possibly affecting KC proliferation 
and differentiation.  
TNIP1 appears to play important roles in regulating multiple receptor 
mediated signal pathways— from the membrane bound TNFR (28, 67, 100) 
signaling cascades to modulating the transcriptional activity of nuclear PPAR (24) 
and RAR (23). Additionally, increased expression of TNIP1 has been implicated 
in several disease states, including psoriasis (34, 52). Though TNIP1’s specific 
role has not been identified in these diseases, our results observed TNIP1 
overexpression reduced expression of several HSPs, a group of proteins whose 
expression also increases during psoriasis. These results show a discord in 
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these findings because increased levels of both TNIP1 and HSPs were 
observed. A potential explanation could be that, while increased TNIP1 levels 
result in reduced HSP expression, the inflammation-induced levels of HSPs 
could be greater than that found if TNIP1 expression was not increased. If TNIP1 
levels were reduced in psoriasis, more HSPs could be observed in psoriatic 
lesions, which would protect the cell from further inflammation-induced damage.  
Using NHEK cells, we were able to determine whether TNIP1 has an 
effect on HSPs in undifferentiating (low Ca2+ in the media) or a mixed population 
of undifferentiated and differentiated (high Ca2+ in the media) KCs (101). To 
generate a greater change in the cell population, the high calcium cultured 
NHEKs were grown an extra 3 days after collecting the low calcium cultured 
cells. The extra time allowed to grow in addition to the increased calcium 
concentration further induces KC differentiation. Using undifferentiating vs. 
differentiating cultured NHEK cells, we observed the TNIP1-mediated reduction 
of HSPA1A and HSPA6 only in the mixed population with differentiating 
keratinocytes. These results are consistent with the HaCaT KC data because the 
cell culture conditions for the HaCaTs are also grown using high calcium media 
(1.45 mM Ca2+). Thus, the HaCaT cells contain a mixed population of KCs. 
Interestingly, when we examined two markers of KC differentiation, involucrin 
and keratin 1, we observed a TNIP1-repressive effect on involucrin, but not 
keratin 1. These results suggest TNIP1 reduces the expression of specific genes 
and is not a general repressor of all genes. 
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In this chapter, we used a gene microarray to examine the specific genes 
and functions altered by increased TNIP1 levels in KCs. Results show that 
TNIP1-associated pathways and diseases were altered in response to enhanced 
TNIP1 protein levels. A novel pathway, the cell stress response, was also 
altered, in which HSP mRNA levels were reduced, possibly indicating TNIP1 
could transcriptionally regulate these genes. The TNIP1-mediated repression of 
HSPA1A and HSPA6 extended to a decrease in protein expression further 
suggesting that TNIP1 may alter the cell stress response by inhibiting the 
production of these proteins.  
  
 50 
Chapter 3 
Transcriptional Regulation of HSPA6 in Basal and Stressed Conditions 
Abstract 
Epidermal KCs serve as the primary barrier between the body and environmental 
stressors. They are subjected to numerous stress events and are likely to 
respond with a repertoire of heat shock proteins (HSP). HSPA6 (HSP70B’) is 
described in other cell types with characteristically low to undetectable basal 
expression, but is highly stress-induced. Despite this response in other cells, little 
is known about its control in keratinocytes (KC). We examined endogenous 
human KC HSPA6 expression and defined some responsible transcription factor 
sites in a cloned HSPA6 3kb promoter. Using promoter 5’ truncations and 
deletions, negative and positive regulatory regions were found throughout the 
3kb promoter. A region between -346 to -217 bp was found to be crucial to 
HSPA6 basal expression and stress inducibility. Site-specific mutations and 
DNA-binding studies show a previously uncharacterized AP1 site contributes to 
the basal expression and maximal stress induction of HSPA6. Additionally, a new 
heat shock element (HSE) within this region was defined. While this element 
mediates increased transcriptional response in thermally stressed KCs, it 
preferentially binds a stress inducible KC factor, other than HSF1 or HSF2. 
Intriguingly, this new HSPA6 HSE competes HSF1 binding a consensus HSE 
and binds both HSF1 and HSF2 from other epithelial cells. Taken together, our 
results demonstrate that the HSPA6 promoter contains essential negative and 
positive promoter regions and newly identified transcription factor targets, which 
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are key to the basal and stress inducible expression of HSPA6. Furthermore, 
these results suggest an HSF-like factor may preferentially bind this newly 
identified HSPA6 HSE in HaCaT KCs.  
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Introduction 
Properly controlled heat shock protein (HSP) gene expression is integral 
to maintaining and restoring cell homeostasis under basal and stressed 
conditions, respectively. Although initially known by their transcription induction 
from thermal stress, HSP expression is also increased in response to toxic 
chemical and UV light assaults (71). Additionally, the characterization of dozens 
of HSP genes across multiple families established that several members are 
constitutively expressed, accounting for their availability in “house-keeping” 
chaperone function (73). As might be expected, within and across HSP families 
there are some coding sequence similarities, common substrate targets, and 
shared transcriptional control by HSF (heat shock factor) (102, 103). However, 
these shared qualities belie the non-redundant role of several HSP identified in 
recent reports (77-79, 104). HSPA1A (HSP70) is an important protein chaperone 
in unstressed conditions and is crucial to prevent stress-induced cell death. While 
closely related to HSPA1A, HSPA6 (HSP70B’) has similar yet distinct functions 
and its expression patterns (79, 105) vary between cell types and cell densities 
(83).  
Like HSPA1A, HSPA6 expression is essential to increasing survival of 
cells exposed to increased temperatures or chemicals. Single or double siRNA-
mediated knockdown of HSPA1A and/or HSPA6 suggest that while both HSPs 
are important to increasing cell survival, HSPA6 may be a secondary regulator of 
stress compared to HSPA1A (79). Decreased expression of HSPA6 did reduce 
the cell viability after a 42C heat stress or proteasome inhibitor MG-132 
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treatment, suggesting its importance in cell survival. HSPA6 likely forms 
complexes with HSPA1A and DNAJB1 (HSP40) (82, 106) to confer its protective 
function. Despite some HSPA6/HSPA1A overlap in facilitating cell survival, 
further work showed they have distinct protein substrates. Compared to 
HSPA1A, HSPA6 has higher affinity for unfolded p53 but has no effect in 
refolding the luciferase enzyme and peroxisomal proteins (77, 78). Better 
definition of HSPA6 gene expression levels and the protein factors/promoter 
elements contributing to it would improve our understanding as to its availability 
or inducibility to meet these specific protective chaperone/refolding functions.  
HSPA6 production under non-stressed conditions is variable, from not 
detected, to low expression levels, possibly dependent on cell type (81, 82) and 
growth condition differences (83). Its capacity for significant induction under 
stressed conditions has been well-documented but what controls this or basal 
expression has mostly been elucidated using a ~287 bp minimal promoter (84-
86). To enhance our understanding of HSPA6 production in other cell types and 
control over its basal and inducible transcription, we examined HSPA6 
expression in epidermal KCs and what might contribute to control of inducible 
and any basal expression. Various HSPs in KCs serve as a cadre of molecular 
chaperones and stress response proteins both for protein folding during cell 
differentiation and epidermal response to topical assaults. Insufficient HSP 
expression in KCs has detrimental consequences including i) inadequate 
integration of cytoskeletal and non-cytoskeletal proteins to generate the skin’s 
barrier and ii) failure to cope with or recover from stresses as evidenced by poor 
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or absent wound healing (107, 108). In brief, we found human KCs have 
significant capacity for HSPA6 induction at both mRNA and protein levels 
compared to the related HSPA1A. Additionally with computational analysis, 
cloning, and functional assessment of ~3kb of the HSPA6 promoter we found 
previously unidentified regions exerting negative or positive effects over basal 
expression as well as a novel (heat shock element) HSE upstream of those 
previously known (85). Constitutive and strikingly inducible HSPA6 expression in 
combination with complex transcriptional regulation suggest it may be positioned 
to contribute significant chaperoning as well as stress-protective functions to 
epidermal KCs.  
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Materials and Methods 
Cell culture  
HaCaT, SCC13, MCF7, HeLa, HepG2 and dermal fibroblasts were cultured in a 
3:1 DMEM/F12 media containing 10% FBS (Thermo Scientific HyClone, Logan, 
UT), 100U/ml penicillin, and 100 mg/ml streptomycin. HT29 cells were cultured in 
McCoy’s 5a modified media containing 10% FBS, supplemented with 1% non-
essential amino acids (NEAA), 100U/ml penicillin, and 100 mg/ml streptomycin. 
Caco2 cells were cultured in MEM media containing 20% FBS and supplemented 
with 1% NEAA, 1% pyruvate, 100U/ml penicillin, and 100 mg/ml streptomycin. All 
cells were grown in a 37C with 5% CO2 humidified incubator. For mRNA and 
protein analyses, cells were plated at 1.5 x 105 and 6.8 x 105 cells per well in 24- 
or 6-well plates, respectively. Twenty-four hours later, cells were stressed for 1 
hour in a 42C water bath (control cells were immersed in a 37C water bath) and 
returned to a 37C incubator for the indicated recovery time. Cells were collected 
for total RNA using the RNeasy kit (Qiagen, Valencia, CA) or protein using RIPA 
lysis buffer (10 mM Tris, 150 mM NaCl, 1% deoxycholic acid, 1% Triton, 0.1% 
SDS) supplemented with Halt Protease Inhibitor (Thermo Scientific, Waltham, 
MA). For transfection analysis, cells were plated to 70% confluency in 24-well 
plates. Twenty-four hours later, cells were transfected as described below.  
 
Real-Time quantitative PCR analysis 
Reverse transcription was performed using aliquots from the total RNA used for 
the microarray using the iScript reverse transcriptase (BioRad, Hercules, CA). 
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Gene expression changes were analyzed using POWER SYBR green master 
mix (Life Technologies, Grand Island, NY). Real-time PCR was performed using 
Applied Biosystems 7500 Fast Real-Time PCR system. Data analysis was 
carried out on ABI 7500 software using the ΔΔCT method. The primer sequences 
used and reaction conditions are listed on Table 2.1. All data were normalized to 
the ribosomal proten L13a (RPL13a) (99).  
 
Immunoblot analysis 
Whole-cell lysates were prepared in RIPA buffer and the protein concentration 
was determined using the 660 nm Protein Assay (Thermo Pierce). Ten 
micrograms of protein were separated by SDS/PAGE, transferred to 
nitrocellulose membranes, rinsed with nanopure water and treated with Qentix 
(Thermo Scientific Pierce). Blots were incubated in blocking buffer consisting of 
5% (w/v) non-fat dried milk, phosphate-buffered saline, and 0.1% Tween 20, then 
probed with HSP70B’ antibody (ADI-SPA-754) at 1:1000 dilution (Enzo Life 
Sciences, Farmingdale, NY) or anti-HSPA1A antibody (ADI-SPA-810) at 1:1000 
dilution (Enzo Life Sciences) (82, 83) followed by HRP (horseradish peroxidase)-
conjugated secondary goat anti-mouse antibody at 1:10,000 dilution 
(PerkinElmer, Branford, CT). Blots were subsequently probed with -actin 
antibody (ab8227) at 1:5,000 dilution (Abcam, Cambridge, MA) followed by HRP-
conjugated secondary goat anti-rabbit antibody at 1:20,000 dilution 
(PerkinElmer). Between probing steps, blots were washed with 0.2% Tween20 in 
phosphate-buffered saline. Detection of binding was determined with enhanced 
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chemiluminescence reagents (Thermo Scientific Pierce). Band signals were 
digitally captured and analyzed using the Kodak image station CCF and 
Carestream molecular imaging software. 
 
Generation of luciferase constructs 
The HSPA6 promoter containing the -2963 to +48 bp sequence (herein referred 
to as -3 kb-luc) was PCR amplified from human genomic DNA (cat# 636401) (BD 
Biosciences, San Jose, CA) using forward: 5’-GAT GGG TAC CTC ATC TTG 
AAT TCC CAC AAC ACA TGG-3’  and  reverse: 5’-GGC TGA AGC TTA GTG 
AGG CTC TCC CTG CGG TTT CTC T-3’ with added KpnI and HindIII sites 
(underlined), respectively for insertion into the promoterless vector pGL4.10 
(Promega, Madison, WI) using the restriction sites indicated. 5’-promoter 
truncations (-1230, -647 and -70 -luc) were performed by using the upstream 
KpnI site and native restriction enzyme sites BglII, EcoRI and NruI, respectively. 
Digested sites were blunted and ligated. Internal promoter deletions were 
performed using the Quikchange Lightning site-directed mutagenesis kit (Agilent, 
Santa Clara, CA). Constructs ΔA, ΔB, ΔC, and ΔD were generated using the -
1230 luc; constructs ΔE, ΔF, ΔG, and ΔH were generated using the -647 luc. 
Fragment G site specific mutants were generated using the Quikchange 
Lightning site-directed mutagenesis kit. The WHN, HSE, MZF1, C/EBP, AP1 and 
Zfx sites were mutated as indicated (Table 1). Sites were determined using NHR 
Scan (109), Nubiscan (110) and MatInspector (111) web-based software. To 
generate the wild type (WT)-G-tk-luc, AP1 mutant (mt)-G-tk-luc, and HSEmt-G-
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tk-luc construct, the HSPA6 G region was amplified via PCR using primers 
flanked by KpnI sites. The pGL4.10 construct containing the thymidine kinase (tk-
luc) minimal promoter was used to insert the HSPA6 WT, AP1mt or HSEmt 
fragment G. All HSPA6 3kb isolate, all site-directed mutants, and deletion 
constructs were confirmed by sequencing (UConn Biotech Center). 
 
Plasmid transfections 
HaCaT cells were plated to 70% confluency 24 hours prior to transfections using 
24-well plates. Eight hours prior to transfection, media was replaced with 0.5 mL 
serum-containing 3:1 DMEM/F12 media. The appropriate HSPA6 promoter 
pGL4.10 plasmid (200 ng) and pCMV- Galactosidase (100 ng) was transfected 
using Fugene6  (Promega) using 100 μL serum-free media. Twenty-four hours 
later, cells were stressed for 1 hour in a 42C water bath (control cells in a 37C 
bath) and returned to a 37C incubator for 4 hours. Cells were then collected and 
assayed for the luciferase activity (Promega), protein concentration (Pierce), and 
-galactosidase activity (96).  
 
Electrophoretic mobility shift assay (EMSA) 
Nuclear extracts were prepared from HaCaT or HeLa cells as previously 
described (44). Protein concentrations were determined by BCA protein assay 
(Pierce, Rockford, IL). Oligomers (Integrated DNA Technology, IDT, Coralville, 
IA) were annealed and end-labeled with 32P-ATP (Perkin Elmer). EMSA 
oligonucleotide probe sequences are shown on Table 2. Fifteen or ten 
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micrograms of nuclear extracts were incubated with radiolabeled HSE or AP1 
oligomers, respectively. For AP1 EMSAs, nuclear extracts were preincubated 
with the appropriate antibodies or unlabeled competition oligomers 1 hour or 15 
minutes, respectively, at room temperature prior to the addition of the 
radiolabeled oligonucleotide probes. The mixture was incubated at room 
temperature for 30 minutes and then loaded into a 6% polyacrylamide gel. Gels 
were electrophoresed at 3.5mA/gel in 0.5X TBE buffer for 10 hours at 4°C. For 
HSE EMSAs, nuclear extracts were preincubated with unlabeled competition 
oligomers 15 minutes at room temperature prior to the addition of the 
radiolabeled oligonucleotide probes. Antibodies were added and the mixture was 
incubated at room temperature for 20 minutes, then on ice for 10 minutes. 
Samples were loaded on a 4% polyacrylamide gel and electrophoresed at 
3.5mA/gel in 0.5X TBE buffer for 8 hours at 4°C. Anti- c-Jun (SC-45X), c-Fos 
(SC-52X), HSF1 (SC-9144x) and HSF2 (SC-13056X) antibodies were obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA). Gels were dried and exposed 
to Amersham Hyperfilm MP (GE, Buckinghamshire, UK) for at least 16 h at -80°C 
with intensifying screens. Films were developed using a Kodak X-Omat 2000. 
 
Statistical analysis 
All data were analyzed using Prism Software version 5 (GraphPad) (La Jolla, 
CA). Student’s t-test was used to compare between paired results. ANOVA with 
Newman Keuls post hoc was used to compare between grouped results, when 
necessary. Statistical significance was defined as p  0.05.  
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Table 3.1. Site-directed mutagenesis primer sequences. Underlined sequences 
denote mutations within the binding site. 
 
Site name  Sequence within HSPA6  Mutated sequence  
WHN ACGC  ATAC  
HSE  GGGAGGAGCTAGAACCTTCC  GGGAGGAGCTAATTCCTTCC  
MZF1  GCGGGGAAGGT  GCGTAGAGGGT  
C/EBP  CTCAGGCTGCTGAAA  CTCATGCACTTGTCA  
AP1  TGAGTCA  TTAGTTA  
ZFX  CTGGCCTGGCG  CTAAGATGGCG  
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Table 3.2. Oligomers used for EMSA probes. Underlined sequences denote 
mutations within the binding site. The predicted HSE mutation encompasses one 
HSE repeat, whereas the double mutant encompasses two HSE inverted 
repeats.  
 
Oligomer name  Primer sequence  
Predicted AP1 top  CTAGCAGCAGCCTGAGTCAGAGGCGGG  
Predicted AP1 bottom CTAGCCCGCCTCTGACTCAGGCTGCTG  
AP1 consensus top  CTAGCGCTTGATGACTCAGCCGGAA  
AP1 consensus bottom  CTAGTTCCGGCTGAGTCATCAAGCG  
Predicted AP1 mutant top  CTAGCAGCAGCCTTAGTTAGAGGCGGG  
Predicted AP1 mutant bottom  CTAGCCCGCCTCTAACTAAGGCTGCTG  
Predicted HSE top  CTAGGGGAGGAGCTAGAACCTTCCCCGCA  
Predicted HSE bottom  CTAGTGCGGGGAAGGTTCTAGCTCCTCCC  
HSE consensus top  CTAGCGAAACCCCTGGAATATTCCCGACC  
HSE consensus bottom  CTAGGGTCGGGAATATTCCAGGGGTTTCG  
Predicted HSE mutant top  CTAGGGGAGGAGCTAATTCCTTCCCCGCA  
Predicted HSE mutant bottom  CTAGTGCGGGGAAGGAATTAGCTCCTCCC  
Predicted HSE double mutant top  CTAGGGGAGGAGCCCATTATAGTAGCGCA  
Predicted HSE double mutant bottom  CTAGTGCGCTACTATAATGGGCTCCTCCC  
 
  
 62 
Results 
Constitutive and inducible expression of HSPA6 in KCs 
Basal and induced levels of HSPA6 were determined in HaCaT KCs under 
standard culture and thermal stress conditions. Basal expression of HSPA6 was 
detected in unstressed cells with several fold increase in protein levels observed 
at 8- and 24-hours post heat shock (Fig 3.1, top panel). HSPA6 mRNA was 
highly upregulated immediately following heat stress, then gradually decreased 
over 8-12 hours after the stress period to levels similar to basal expression (Fig 
3.1, bottom panel). To validate the heat shock, HSPA1A protein and mRNA 
expression was also examined. The induction pattern of HSPA1A protein and 
mRNA was similar to HSPA6, but to a lesser fold induction than HSPA6 (Fig 3.2). 
Variable levels of HSPA6 and HSPA1A were also detected in other epithelial 
(HT29, MCF-7, Caco2, HepG2) and epidermis-derived (SCC13), cells with 
relatively little detected in dermal fibroblast cells (Fig 3.3) under standard (non-
stressed) culture conditions. HSPA6 cell-type range of expression and induction 
suggested a combination of ubiquitous and stress-specific factors may control its 
gene expression.  
 
Determining specific transcription factor binding sites within the HSPA6 promoter 
To guide physical isolation of the human HSPA6 promoter, we started with 
an in silico examination of sequences upstream of the referenced transcription 
start site (112) and 5’UTR of the NCBI mRNA reference sequence (113) 
NM_002155.3. NHR Scan (109), NubiScan (110) and MatInspector (111)  
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Figure 3.1 
 
 
 
Figure 3.1. Basal and heat-inducible expression of HSPA6 in HaCaT KCs. 
Top panel. HSPA6 protein expression before (0 hr) and post-heat shock (8 and 
24 hr). Samples shown from duplicate cultures. Bottom panel. HSPA6 mRNA 
expression before (0 hr) and post-heat shock (1, 2, 3, 4, 8 and 12 hr). Unless 
otherwise indicated, all cells are unstressed. -actin used as western blot loading 
control. 
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Figure 3.2 
 
 
 
Figure 3.2. Basal and heat-inducible expression of HSPA1A in HaCaT KCs. 
Top panel. HSPA1A protein expression before (0 hr) and post-heat shock (8 and 
24 hr). Samples shown from duplicate cultures. Bottom panel. HSPA1A mRNA 
expression before (0 hr) and post-heat shock (1, 2, 3, 4, 8 and 12 hr). 
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Figure 3.3 
 
 
Figure 3.3. Expression of HSPs in various cell types. HSPA6 (top panel) and 
HSPA1A (bottom panel) protein expression in various cells. Unless otherwise 
indicated, all cells are unstressed. -actin used as western blot loading control. 
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analysis suggested high scoring hits for diverse transcription factors up through 
the first few thousand base pairs of DNA. Germane to our laboratory’s interest in 
nuclear receptors, putative peroxisome proliferator activated receptor (PPAR) 
and retinoic acid receptor (RAR) response elements were located between ~ -
3000 to -1200 bp upstream of the transcriptional start site. To determine HSPA6 
expression responsiveness to these and other transcription factors, we isolated 
and cloned its promoter region from -2962 to +48 bp (-3 kb) into a pGL4.10 
luciferase reporter gene construct (Fig 3.4). Endogenous HSPA6 expression and 
HSPA6 -3 kb-luc promoter activation marginally increased only in presence of 
high concentration of PPARγ ligand or overexpressed PPARγ receptor and high 
concentration of ligand, respectively (data not shown). Since PPARγ has low 
expression in KCs, we hypothesized that other transcription factor(s) may be 
responsible for the expression of HSPA6.  
Searching the promoter for other predicted sites, further in silico promoter 
analysis was performed. In addition to searching for factors that contribute to 
HSPA6’s basal expression, we searched for heat shock elements (HSE) that 
may contribute to the stress inducibility of HSPA6. Our analysis found previously 
recognized sites such as two HSEs at -181 to -161 bp and -100 to -60 bp, an 
AP1 site at -139 to -132 bp, and a predicted TATA box within the proximal 
HSPA6 promoter, -283 to +110 bp (Wada 2007, Leung 1990). Importantly, 
previously unrecognized potential transcription factor binding sites (such as AP1 
and upstream HSEs) (Fig 3.5) were identified suggesting additional control 
possibilities for basal and inducible HSPA6 promoter activity.   
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Figure 3.4 
 
 
Figure 3.4. Native restriction enzyme sites within the HSPA6 3kb promoter. 
Diagram of the HSPA6 promoter from -2952 to +48 bp. Restriction enzyme sites 
shown and used for generating promoter truncation constructs. Yellow region 
indicates start of the luciferase reporter gene.  
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Figure 3.5 
 
 
 
Figure 3.5. In silico analysis of the HSPA6 3kb promoter. Top panel. HSPA6 
promoter sequence between -1300 to -1100 bp. Red sequences denote putative 
HSE. Bottom panel. HSPA6 promoter sequence between -700 to +48 bp. Red 
sequences denote putative HSE. Blue sequences denote putative AP1 sites. 
Nucleotides in boldface denote predicted TATA box. Underlined sections denote 
previously identified HSEs. Italicized section denotes previously identified AP1 
site.  
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HSPA6 promoter contains negative and positive basal regulatory regions 
To narrow down the responsive regions involved in HSPA6 regulation, we 
generated a series of 5’ truncation constructs using naturally occurring restriction 
enzyme sites (Fig 3.4). Transfection results from the truncated HSPA6 promoter 
constructs from unstressed cells showed the -647-luc had increased luciferase 
activity compared to the “minimal” -70-luc. Interestingly, extending the 5’ 
promoter to -1230 bp and further led to a reduction of luciferase activity back to 
the minimal promoter levels (Fig 3.6, left panel). These results suggest the 
regulation of unstressed HSPA6 includes both negative (between -1230 to -648 
bp) and positive (between -647 to -70 bp) elements. Heat-induced expression 
(Fig 3.6, right panel) was observed with promoter regions inclusive of sequence 
upstream of the previously described -181 and -100 bp HSEs. Notably however, 
the fold induction of the -1230 bp and -3 kb were significantly greater than the 
fold induction of the -647 bp reporter suggesting other proactive elements 
involved in maximal stress response.  
To further guide our search for HSPA6 promoter regions contributing to its 
overall basal activity and stress response, we generated several constructs 
deleting ~150 bp lengths within the -1230-luc or -647-luc constructs. Deletions 
within the -1230-luc, ΔA-, ΔB-, ΔC- and ΔD-luc, (Fig 3.7, left panel) showed 
removal of fragment D (-806 to -648) increased the promoter activity 76%, 
suggesting possible negative regulatory element(s) within this region (Fig 3.7, 
middle panel). The stress responsiveness of ΔA-, ΔB-, ΔC- and ΔD-luc were also 
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compromised as a decrease in fold induction was observed with these constructs 
compared to full-length -1230- 
luc (Fig 3.7, right panel). Internal promoter deletions within the -647-luc, ΔE-, ΔF-
, ΔG- and ΔH-luc (Fig 3.8, left panel), suggested fragments F, G and H each 
contribute to the activation of the HSPA6 promoter. Removal of fragments F or H 
reduced the promoter activity to ~35% compared to the full-length -647-luc. 
Deletion of fragment G (-346 to -217 bp) (Fig 3.8, middle and right panels) led to 
the complete loss of the HSPA6 promoter activity. While deletion of each 
individual fragment reduced the heat inducibility of the promoter, the induction of 
ΔG-luc was significantly reduced back to basal levels of -647-luc. Because 
removal of fragment G lost all promoter activation we focused on determining the 
possible site(s) within this region that are crucial for the activation of the HSPA6 
promoter. 
 
A novel AP1 site within -346 to -217 bp contributes to the activation of the 
HSPA6 promoter 
A transcription factor binding site search within fragment G (-346 to -217 bp) 
determined 6 top-scoring predicted elements: WHN, HSE, MZF1, C/EBP, AP1 
and ZFX (Fig 3.9). We generated site-specific mutants within the -647-luc 
constructs to determine which binding site may contribute to the unstressed 
(37C) expression of HSPA6. Of these candidate sites, mutation of WHN, HSE 
and MZF1 had no significant effect on the basal HSPA6 promoter activation,  
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Figure 3.6 
 
 
Fig 3.6. Determining the transcriptionally regulated regions within the 
HSPA6 promoter. Left panel. Promoter activation at basal, 37C conditions. The 
graph is normalized to the -70-luc. Right panel. Promoter induction due to a 1 
hour, 42C heat stress. Graph shown as fold inducibility compared to 37C 
condition. Letters denote statistical significance using ANOVA with Newman 
Keuls post-hoc, p < 0.05. Bars are mean + SEM from n=3, triplicate experiments.  
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Figure 3.7 
 
 
Figure 3.7. Localizing the repressible region within the HSPA6 promoter. 
Left panel. Internal deletions A, B, C, and D between -1230 to -648 denoted as 
the dotted line. Middle panel. Promoter activation at basal, 37C conditions. 
Graph shown as percent of -1230-luc. Right panel. Promoter induction due to a 1 
hour, 42C heat stress. Graph shown as fold inducibility compared to 37C 
condition. Letters denote statistical significance using ANOVA with Newman 
Keuls post-hoc, p < 0.05. Bars are mean + SEM from n=3, triplicate experiments. 
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Figure 3.8 
 
 
Figure 3.8. Localizing the basal and inducible regions within the HSPA6 
promoter.  Left panel. Internal deletions E, F, G, and H between -647 to -70 
denoted as the dotted line. Middle panel. Promoter activation at basal, 37C 
conditions. Graph shown as percent of -647-luc. Right panel. Promoter induction 
due to a 1 hour, 42C heat stress. Graph shown as fold inducibility compared to 
37C condition. Letters denote statistical significance using ANOVA with 
Newman Keuls post-hoc, p < 0.05. Bars are mean + SEM from n=3, triplicate 
experiments. 
 
  
 74 
whereas C/EBP and ZFX specific mutants resulted in an ~50% increase in the -
647-luc promoter activity. Only mutation of AP1 resulted in activity loss. This local 
length of the HSPA6 promoter seems to share the trait of positive and negative 
control we saw upstream with -1230 bp and -3 kb lengths. Thus the -346 to -217 
bp region is likely crucial for proper positive and negative promoter regulation of 
within the HSPA6 native promoter.  
To independently assess regulation conferred by region G, we fused the -
346 to -217 bp region to the minimal tk- promoter (Fig 3.10). This G-tk-luc 
construct did not significantly change the luciferase activity compared to the tk-
luc construct. When the AP1 site was mutated, a ~54% reduction was observed 
compared to wild type fragment G tk-luc (G-WT tk-luc). These results suggest 
fragment G activation potential is promoter context dependent, contributing to the 
native HSPA6 promoter but not a heterologous (tk) promoter. These results are 
consistent with the predicted -244 bp AP1 site contributing to the promoter 
activation of HSPA6. 
To test for physical association of AP1 to the predicted binding site, 
electrophoretic mobility shift assays (EMSAs) were performed. Using the 
predicted HSPA6 -244 bp AP1 site as the 32P-labeled oligomers, our EMSA 
results show an AP1 specific band competed by an unlabeled HSPA6 AP1 site 
and consensus AP1 site, but not by the mutated AP1 site. Addition of AP1 
subunit (cJun, cFos, or combined) specific antibody disrupted the band species 
in the cFos and the combined cJun/cFos lanes (Fig 3.11). Based on reporter  
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Figure 3.9 
 
 
Figure 3.9. Searching for transcription factor binding sites between the -346 
to -216 bp region of HSPA6. Site specific mutations within the -647-luc 
construct. Filled shapes indicate wild-type elements. Specific site mutants are 
shown as empty shapes. Graph shown as percent of -647-luc. Letters denote 
statistical significance using ANOVA with Newman Keuls post-hoc, p < 0.05. 
Bars are mean + SEM from n=3, replicate experiments.  
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Figure 3.10 
 
 
Figure 3.10. Characterization of the -244 bp AP1 site. AP1 specific mutant 
within the fragment G-tk-luc construct. Graph shown as percent of tk-luc. Letters 
denote statistical significance using ANOVA with Newman Keuls post-hoc, p < 
0.05. Bars are mean + SEM from n=3, replicate experiments.  
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Figure 3.11 
 
 
Figure 3.11. EMSA binding analysis of AP1 proteins c-Jun and c-Fos to the  
-244 bp AP1 site. Antibodies include non-specific IgG (I), anti-c-Jun (J), anti-c-
Fos (F) or both anti-c-Jun and anti-c-Fos (B). Non-radiolabeled competitor 
oligomers include self HSPA6 AP1 site (S), consensus oligomer (C) or mutated 
AP1 (M) at 5 or 50-fold excess.  
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construct and the protein-DNA interaction experiments, HSPA6 -244 to -237 is a 
newly identified, functional AP1 site contributing to transcriptional activity of the 
HSPA6 promoter in unstressed conditions. 
 
A novel heat shock element within -346 to -217 bp contributes to the activation 
and thermal induction of the HSPA6 promoter 
In addition to promoter elements that might contribute to control of basal 
activity, our transcription factor search predicted a previously unreported heat 
shock element within region G. To test its contribution, or how other sites might 
affect overall stress response, we tested 6 site-specific mutants (Fig 3.12) under 
basal versus stressed conditions to determine fold induction. Mutations within the 
WHN, HSE, HSE/MZF1, and AP1 sites significantly reduced the stress 
inducibility of -647-luc, whereas C/EBP and ZFX specific mutations had no 
significant effect on stress inducibility. Taken together, these separate binding 
sites each contribute to the heat inducibility of the promoter and likely have an 
additive effect in order to gain maximal stress inducibility.  
To address the heat stress inducibility of the fragment G HSE, we fused 
the -346 to -217 bp region to the tk-luc construct. This specific construct is 
advantageous as it tests the fragment G candidate HSE independent of the 
previously described HSEs more proximal to the transcriptional start site. The G-
WT-tk-luc was heat induced ~20-fold compared to the tk-luc. In contrast, the G-
HSEmt tk-luc abolished all stress induction (Fig 3.13). These results show that 
the -284 bp HSE contributes to the increased expression of HSPA6 due to stress 
induction. 
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Using the functionally defined HSPA6 -284 bp HSE as EMSA probe, a 
band pattern observed from unstressed HaCaT KC nuclear extracts increases in 
intensity with heat shock. The binding species could be competed with unlabeled 
wild type, mutant, and double mutant HSPA6 HSE site, but not unlabeled 
consensus HSE oligomers  (Fig 3.14, top panel). Additionally, HSF1 or HSF2 
specific antibodies did not affect the band pattern (Fig 3.14, bottom panel). Using 
32P-labeled consensus HSE oligomers as EMSA probe, our unlabeled HSPA6 
HSE was able to compete the HSF1 specific band, suggesting that the -284 bp 
HSE can compete for HSF1 under these circumstances (Fig 3.15).  
 In an attempt to resolve these disparate results (HSE -284 transcriptionally 
active in mediating thermal stress response but not performing as a classic HSF-
binding HSE in vitro) we compared the HSPA6 -284 bp HSE binding with that of 
a consensus HSE (derived from the HSPA1A promoter) (114) with an alternate 
nuclear protein source, HeLa cells. Using HeLa nuclear extracts, the HSPA6 -
284 bp HSE generated a binding complex recognized by HSF1 antibody from 
unstressed and stressed cells, while a HSF2 complex was recognized from 
stressed cells (Fig 3.16). As a control, we confirmed that the same extracts were 
generating a HSF1-containing complex on the A1A consensus HSE (Fig 3.17). 
Together, these transcription activation and EMSA results suggest a stress-
associated transcription factor, other than HSF1 or HSF2, binds the -284 bp HSE 
in HaCaT KCs to activate the HSPA6 promoter. Intriguingly, when HeLa cells are 
used, HSF1 and HSF2 can bind this site suggesting a cell specific transcription 
factor binding of this HSE.  
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Figure 3.12 
 
 
Figure 3.12. Searching for heat responsive elements between -346 to -216 
bp region of HSPA6. Site specific mutations within the -647-luc construct. 
Specific Filled shapes indicate wild-type elements. Specific site mutants are 
shown as empty shapes. Graph shown as fold heat induction. Letters denote 
statistical significance using ANOVA with Newman Keuls post-hoc, p < 0.05. 
Bars are mean + SEM from n=3, replicate experiments.  
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Figure 3.13 
 
 
Figure 3.13. Characterization of the -284 bp HSE. HSE specific mutant within 
the fragment G-tk-luc construct. Graph shown as fold heat induction. Letters 
denote statistical significance using ANOVA with Newman Keuls post-hoc, p < 
0.05. Bars are mean + SEM from n=3, replicate experiments.  
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Figure 3.14 
 
 
 
Figure 3.14. EMSA binding analysis of HaCaT HSF proteins to the -284 bp 
HSE. EMSA of HSPA6 HSE with HaCaT KC nuclear extracts incubated with 
unlabeled competitor oligomers. d. As in c with IgG, HSF1 or HSF2 specific 
antibodies. Antibodies include non-specific IgG (I), anti-HSF1 (1), or anti-HSF2 
(2) . Non-radiolabeled competitor oligomers include self HSPA6 HSE site (S), 
consensus HSE (C), mutated HSE (M) or double mutated HSE (D) at 10 or 100-
fold excess.   
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Figure 3.15 
 
 
Figure 3.15. EMSA binding analysis of HaCaT HSF proteins to a consensus 
HSE. EMSA of consensus HSE with HaCaT KC nuclear extracts. Antibodies 
include non-specific IgG (I), anti-HSF1 (1), or anti-HSF2 (2). Non-radiolabeled 
competitor oligomers include self HSPA6 HSE site (S), consensus HSE (C) or 
mutated HSE (M) at 10 or 100-fold excess. Arrowhead denotes supershift.  
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Figure 3.16 
 
 
Figure 3.16. EMSA binding analysis of HeLa HSF proteins to the -284 bp 
HSE. EMSA of HSPA6 HSE with HeLa nuclear extracts. Antibodies include non-
specific IgG (I), anti-HSF1 (1), or anti-HSF2 (2). Arrowheads denote supershift.  
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Figure 3.17 
 
 
Figure 3.17. EMSA binding analysis of HeLa HSF proteins to a consensus 
HSE. EMSA of consensus HSE oligomer with HeLa nuclear extracts. Antibodies 
include non-specific IgG (I), anti-HSF1 (1), or anti-HSF2 (2). Arrowhead denotes 
supershift.  
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Discussion 
Although discovered over 20 years ago (112), HSPA6’s role as a 
chaperone and stress-responding protein have only been recently studied (79, 
82, 105, 115). Relative to other members of its HSP70 family, little is known 
about HSPA6 transcriptional regulation in stressed and unstressed cells (85, 86). 
Basal expression of HSPA6 was not detected in basal, unstressed cells using a 
range cell types; however highly stress inducible expression was noted with a 
wide range of expression (82, 83, 116).  
Using a previously characterized, highly specific HSPA6 antibody (82), our 
studies were consistent with a recent report (81) demonstrating detectable but 
variable levels of constitutive HSPA6 protein and mRNA in all cell types 
examined. Basal expression of HSPA6 could be dependent on different cell 
growth conditions and may address the HSPA6 detection here but not in prior 
analysis of HaCaT KCs (74). The majority of the cells grown in our lab (HaCaT, 
SCC13, MCF7, HeLa, HepG2 and dermal fibroblasts) are grown in a 3:1 ratio of 
DMEM:Ham’s F12 or are grown in DMEM supplemented with non-essential 
amino acids (HT29 and Caco2). Modifying the ingredients of the cell culture 
media has led to increased expression of HSPs (117, 118). Gomez-Sucerquia 
and colleagues used cell culture media supplemented with non-essential amino 
acids, which could contribute to the basal expression of HSPA6 (81). In addition 
to the media composition, the cell density also affects the expression of HSPA6. 
Noonan and colleagues observed that HT-29 cells plated at a low cell density 
had increased expression of HSPA6 compared to cells cultured at a high cell 
 87 
density (83). Upon thermal stress, HaCaT KCs responded with induction of both 
HSPA1A and HSPA6, although the latter to many more fold at the mRNA level. 
Given its detection in non-stress conditions ((81) and our report), its capacity for 
significant fold induction (82, 119), and its likely contribution to post-stress cell 
survival (83) we sought to better define control of its basal and stress-inducible 
expression in KCs, a cell type with wide dependence on chaperone function and 
likely to encounter diverse stress conditions. We found novel elements 
contributing to its basal expression and importantly an upstream HSE likely 
contributing to its maximal induction during a stress response.  
An in silico promoter analysis indicated several candidate regulatory 
elements throughout the first several thousand base pair of the promoter guiding 
our cloning of a 3kb region (-2962 to +48 bp). Prior to our work, Wada and 
colleagues examined the contribution of an AP1 site and 2 HSEs within the 
proximal region (-287 to +110 bp) of the HSPA6 promoter to develop a reporter 
construct sensitive to cadmium chloride exposure (84, 85). Taking advantage of 
longer promoter regions we isolated, we found that a region further upstream (-
807 to -648 bp; here named fragment D) confers negative regulation and 
contributes to heat stress inducibility on HSPA6. The presence of repressive 
regions is consistent not only in the transfection results, but may also explain the 
reduced endogenous expression in several cell types, such as dermal fibroblasts 
and Caco2 cells. If these repressive factors are highly expressed in dermal 
fibroblasts and Caco2 cells, the expression of HSPA6 would be greatly reduced. 
Despite this region’s overall limiting effect on promoter activity, we established a 
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novel HSE in this region (-807 to -648 bp) that contributes to the HSPA6 maximal 
stress inducibility. Furthermore, we observed that a region (-346 to -216 bp, 
fragment G) in our extended promoter, directly upstream of previously identified 
AP1 (-139 bp) and HSEs (-181 and -100 bp) sites, is crucial for the basal and 
heat inducibility of HSPA6 likely by its provision of an additional AP1 site and 
another HSE. To test the activating potential of this region, fragment G was fused 
to a (tk) promoter where it could confer stress responsiveness to this 
heterologous promoter but not raise its basal activity. Interesting, when the AP1 
site was mutated in this fragment, basal activity was reduced suggesting that 
fragment G was a combination of both positive (like AP1) and negative elements 
(as yet to be identified) and that loss of AP1 favored the remaining negative 
control from this region. Nevertheless, given that under basal, unstressed 
conditions, this fragment G region can confer promoter activation in the context 
of the HSPA6 promoter, we sought to determine possible factors contributing to 
this region’s basal and stress inducibility. 
Within fragment G (-346 to -216 bp), six top-scoring transcription factor 
binding sites were predicted: WHN, HSE, HSE/MZF1, C/EBP, AP1 and ZFX. In 
unstressed conditions, site specific mutants within fragment G showed that an 
AP1 site at -240 bp contributes to the HSPA6 promoter activation. Surprisingly, 
our mutation analysis discovered two presumptive repressive elements, C/EBP 
and ZFX (120, 121), within this region. Similar to the full HSPA6 3kb promoter, 
this shorter fragment also contains both positive and negative elements which 
contribute to the overall basal transcription of HSPA6. Consistent with this AP1 
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site contributing to the basal activation of HSPA6, we found that cFos, a typical 
subunit of the AP1 protein dimer, but not cJun binds the AP1 site within fragment 
G. We expect that since the AP1 heterodimer can be made from several subunits 
(cJun, junB, junC, Fra-1, Fra-2, cFos or fosB), the dominant AP1 dimer bound to 
the -240 AP1 binding site could be cFos and another subunit other than cJun. 
Results from the promoter mutation and EMSA analyses confirm that a new AP1 
site within fragment G contributes to the basal and inducible expression of 
HSPA6. Other non-HSF proteins have also been recently shown to contribute 
control over basal and stress-induced HSP expression. Ataxin-3, possibly 
through DNA binding but more likely through its interaction with transcription 
factors, augments the full capacity of the HSP70 (HSPA1A) promoter to thermal 
and chemical stress (122). 
In addition to its basal regulation, we characterized the functional 
elements within -346 to -216 that contribute to its stress inducibility. The 
predicted HSE at -284 bp (gGGAg gAGCt aGAAc cTTCc) contains one imperfect 
site (site 1) and two perfect sites (sites 3 and 4). The HSE specific mutation of 
site 3 prevented the stress inducibility to a similar effect of the deletion of entire 
fragment G, indicating these nucleotides contribute to the only HSE in this region. 
Sites other than the HSE (WHN, HSE/MZF1 and AP1) also appear to contribute 
to the maximal heat induction of HSPA6. The HSE/MZF1 site is labeled as such 
due to the overlap between key nucleotides within these two sites. The mutations 
within MZF1 also affect HSE site 4. We believe that the decrease in stress 
inducibility due to the MZF1 mutation is due to the loss of a core HSE repeat. 
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Mutating the AP1 site, which plays a role in basal activation of HSPA6, also 
reduced the induction compared to the full length, wild type -647-luc. Similar to 
HSPA1A, multiple HSEs (123) and the elements conferring basal activation (124) 
of HSPA6 may be necessary to obtain the maximal stress inducibility. The HSE 
within fragment G may be working in concert with other factors to achieve the 
maximal stress inducibility of HSPA6. Our results show that this HSE is 
necessary for the stress inducibility within -346 to -216 bp region of the HSPA6 
promoter.  
The new HSPA6 HSE we demonstrated at -284 bp provided thermal 
responsiveness both in the context of the HSPA6 promoter and when transferred 
to the heterologous tk promoter. While this sequence was able to bind HaCaT 
KC stress-associated nuclear protein(s) in vitro, it was surprising that these 
binding factors were not recognized by either HSF1 or HSF2 antibodies. 
Intriguingly, when this site was used as a competitor for the 32P-labeled 
consensus HSE, again with HaCaT KC nuclear extracts, it competed HSF1 from 
the consensus probe. To test the binding of our site to HSF, we performed the 
EMSA analysis using nuclear extracts from a different cell type, HeLa cells. Data 
from the HeLa EMSAs suggest our site binds HSF1 under unstressed and 
stressed conditions, and HSF2 primarily in stressed nuclear extracts. It is 
possible that a different HSF family member may bind this HSE, HSF4. This 
transcription factor can compete for HSF1 binding (125), however expression of 
HSF4 has not been tested in KCs. Thus our site may bind one of these HSFs, or 
possibly a different stress-inducible factor. To date, HSF4’s function and 
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expression have mainly been characterized in eye development, playing a role in 
the lens development (126). Altogether, the results from the promoter reports and 
DNA-binding assays show our site as a functional HSE which can bind HSF1 and 
HSF2, but preferentially binds another, yet characterized stress inducible factor 
when presented with HaCaT KC nuclear proteins.  
In the present study, we performed an analysis of HSPA6 promoter to 
search for core basal and inducible transcriptional elements, finding both positive 
and negative regulatory regions. Two factors, AP1 and HSF, contribute to the 
expression of HSPA6. AP1 regulates HSPA6 transcription under both unstressed 
and stressed conditions, whereas a HSF-like factor HSF contributes to the heat 
inducibility of HSPA6. In addition to characterizing these regions, our HSE EMSA 
results suggest an HSF-like factor from HaCaT KCs may preferentially bind the 
HSPA6 promoter warranting further investigation of this possibly novel factor.  
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Chapter 4 
TNIP1-HSP Mechanism of Repression and Overall Keratinocyte 
Consequences 
Abstract 
The increased expression of TNFα-induced protein 3-interacting protein 1 
(TNIP1), a repressor of transcription factor activation or activity, was shown to 
affect the cell stress response through a reduction in HSP expression. HSPs are 
not only important in protecting cells from the harmful effects of various stressors, 
they play key roles as molecular chaperones during basal, unstressed conditions. 
These results suggest TNIP1 could regulate the cell stress response. However, 
its exact role in this process and the mechanism of the TNIP1-mediated 
transcriptional repression is not yet characterized. We hypothesized that TNIP1 
acts on PPAR, RAR or NF-kB, the TNIP1-repressed factors, to reduce the 
expression of HSPs. Using HSPA6 to model the repression on all HSPs, we 
observed TNIP1 does not act through these transcription factors. We further 
localized a ~150 bp region within the HSPA6 promoter and determined several 
predicted transcription factor binding sites, suggesting TNIP1 modulates HSP 
repression through a novel, yet uncharacterized pathway. Additionally, we 
assessed the effect of TNIP1 on keratinocyte proliferation and differentiation. We 
found that a chronic, but not acute, overexpression of TNIP1 blocks keratinocyte 
cell growth to possibly through decreasing the HSP chaperone function.  
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Introduction 
The TNFα-induced protein 3 interacting protein 1 (TNIP1) is a regulator of 
various receptor-mediated signaling pathways, including those initiated by TNF 
receptor TNFR (28, 31, 88) and nuclear receptors (NR) peroxisome proliferator 
activated receptors (PPAR) and retinoic acid receptors (RAR) (23, 24) (Fig 1.3 
TNIP1 pathway figure). This repressive effect results in downstream or direct 
inhibition of transcription factor activation or activity. Typically, a resulting 
outcome of TNFR signaling is the activation of NFκB, a transcription factor 
involved in modulating the immune and stress responses. Through interactions 
with upstream signaling proteins, TNIP1 blocks the nuclear translocation of 
NFκB, therefore preventing the transcription of its target genes. In a separate 
mechanism, TNIP1 directly binds with NRs PPAR or RAR, but not their 
heterodimer parter retinoid X receptor (RXR), in presence of receptor agonist. 
Overall, TNIP1 can be thought of as a direct or indirect repressor of transcription 
factor activation or activity, possibly having an effect on cellular processes or 
diseases (for a recent review on TNIP1, refer to (41)).  
A biological association with inflammatory diseases has also been 
determined for TNIP1 observed at the genetic, transcript, protein or expression 
levels. Through genome wide association scans, TNIP1 promoter and intronic 
single nucleotide polymorphisms (SNPs) were found in inflammatory diseases 
including but not limited to psoriasis, systemic lupus erythematosus and 
rheumatoid arthritis (34, 38, 39, 87). Specific nucleotide or amino acid mutations 
were found at the mRNA and protein level (43, 51). Furthermore, increased 
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TNIP1 levels were linked to psoriasis and rheumatoid arthritis (33, 34). The 
altered expression of TNIP1 in these diseases could lead to aberrant signaling of 
these pathways. While TNIP1 has been associated to these pathways and 
diseases, the specific role and target genes affected by TNIP1 have yet been 
characterized.  
 To search for specific genes and possibly novel pathways affected by 
TNIP1, we overexpressed recombinant TNIP1 using an adenoviral construct in 
HaCaT KCs and performed a gene microarray (Figs 2.1 & 2.2). The results not 
only confirmed TNIP1’s role in these pathways and biological functions, but 
discovered a novel TNIP1-regulated function: regulation of the cell stress 
response (Figs 2.3 & 2.4). Increased expression of TNIP1 in HaCaT 
keratinocytes (KC) repressed the expression levels of heat shock protein (HSP) 
mRNA and protein expression, specifically HSPA6 and HSPA1A by 20- and 3.3-
fold, respectively (Figs 2.5 & 2.6). While best characterized for their role in 
preventing protein unfolding and aggregation during times of cellular stress (71, 
73, 78), expression of these proteins is crucial in unstressed conditions as well. 
They have chaperone functions in aiding proper folding of newly synthesized 
proteins and shuttling of many molecules.  
Expression of both HSPA1A and HSPA6 is essential to increasing survival 
of cells exposed to increased temperatures or chemicals. Pharmacologic 
repression of HSPA1A expression in keratinocytes resulted in reduced resistance 
to UV treatment (93). Furthermore, HSPA1A and HSPA6 specific siRNA-
mediated knockdown suggest that expression of either HSPs are important to 
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increasing cell survival. A reduction of both HSPs led to a greater loss of 
thermotolerance, resulting in reduced cell viability (79). Decreased expression of 
HSPA6 did reduce the cell viability after a 42C heat stress or proteasome 
inhibitor MG-132 treatment, suggesting its importance in cell survival. HSPA6 
likely forms complexes with HSPA1A and DNAJB1 (HSP40) (82, 106) to confer 
its protective function. Despite some HSPA6 and HSPA1A overlap in facilitating 
cell survival, further work showed they have distinct protein substrates. 
Compared to HSPA1A, HSPA6 has higher affinity for unfolded p53 but had no 
effect in refolding the luciferase enzyme and peroxisomal proteins (77, 78).  
In this chapter, we examined the potential mechanism for the TNIP1-
mediated repression of HSPs. We chose HSPA6 because this gene was reduced 
20-fold by increased TNIP1 compared to the 3.3-fold reduction of HSPA1A. We 
isolated and cloned the HSPA6 3 kb promoter to the pGL4.1 luciferase reporter 
gene construct. Surprisingly, our results indicate that TNIP1 does not repress 
HSPA6 through known TNIP1-mediated transcription factors, PPAR, RAR and 
NFκB. This suggests that a novel TNIP1-repressible pathway could inhibit HSP 
expression. Additionally, this work suggests chronic TNIP1 overexpression, but 
not acute, prevents the growth of cultured keratinocytes, suggesting TNIP1 may 
play a role in the keratinocyte proliferation and differentiation process.  
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Materials and Methods 
Cell Culture  
HaCaT KCs (95) were cultured in 37C with 5% CO2 humidified incubator 
in a 3:1 DMEM/F12 media containing 10% FBS (Thermo Scientific HyClone, 
Logan, UT), 100U/ml penicillin, and 100 mg/ml streptomycin. The cells were 
plated on 6- or 24-well plates at a density of 6.8 x 105 or 1.5 x 105 cells per well, 
respectively. Twenty-four hours after, cells were infected with an adenovirus 
construct expressing TNIP1 (Ad-TNIP1) or LacZ as a control (Ad-LacZ) at an 
multiplicity of infection (MOI) of 500 using Polybrene infection reagent (Millipore, 
Billerica, MA) (96). Sixteen hours post-infection, the viral mixture was aspirated 
and media replaced. Twenty-four hours post-infection, cells were collected for 
total RNA using the RNeasy kit (Qiagen, Valencia, CA) or protein using RIPA 
lysis buffer (10 mM Tris, 150 mM NaCl, 1% deoxycholic acid, 1% Triton, 0.1% 
SDS), or were used for further stress assays.  
Cells underwent thermal stress in a 42C water bath for 1 hour; 
unstressed cells were immersed in a 37C water bath for 1 hour (control). Cells 
were allowed various recovery times in a 37C humidified incubator, as indicated.  
 
Real-Time quantitative PCR analysis 
Reverse transcription was performed using aliquots from the total RNA 
used for the microarray using the iScript reverse transcriptase (BioRad, Hercules, 
CA). Gene expression changes were analyzed using POWER SYBR green 
master mix (Life Technologies, Grand Island, NY). Real-time PCR was 
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performed using Applied Biosystems 7500 Fast Real-Time PCR system. Data 
analysis was carried out on ABI 7500 software using the ΔΔCT method. The 
primer sequences used and reaction conditions are listed on Table 2.1. All data 
was normalized to the ribosomal proten L13a (RPL13a) (99).  
 
Generation of luciferase constructs 
The HSPA6 promoter containing the -2963 to +48 bp sequence (herein 
referred to as -3 kb-luc) was PCR amplified from human genomic DNA (cat# 
636401) (BD Biosciences, San Jose, CA) using forward: 5’-GAT GGG TAC CTC 
ATC TTG AAT TCC CAC AAC ACA TGG-3’  and  reverse: 5’-GGC TGA AGC 
TTA GTG AGG CTC TCC CTG CGG TTT CTC T-3’ with added KpnI and HindIII 
sites (underlined), respectively for insertion into the promoterless vector pGL4.10 
(Promega, Madison, WI) using the restriction sites indicated. 5’-promoter 
truncations (-1230, -647 and -70 -luc) were performed by using the upstream 
KpnI site and native restriction enzyme sites BglII, EcoRI and NruI, respectively. 
Digested sites were blunted and ligated. Internal promoter deletions were 
performed using the Quikchange Lightning site-directed mutagenesis kit 
(Agilent). Constructs ΔE, ΔF, ΔG, and ΔH were generated using the -647 luc. 
Fragment G site specific mutants were generated using the Quikchange 
Lightning site-directed mutagenesis kit. Sites were determined using NHR Scan 
(109), Nubiscan (110) and MatInspector (111) web-based software. All HSPA6 
3kb isolate and truncation constructs were confirmed by sequencing (University 
of Connecticut Biotech Center).  
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Plasmid transfections 
HaCaT KCs were plated to 70% confluency 24 hours prior to transfections 
using 24-well plates. Eight hours prior to transfection, media was replaced with 
0.5 mL serum-containing 3:1 DMEM/F12 media. The appropriate HSPA6 
promoter pGL4.10 plasmid (200 ng) and pCMV- Galactosidase (100 ng) was 
transfected using Fugene6  (Promega) using 100 μL serum-free media. Twenty-
four hours later, cells were stressed for 1 hour in a 42C water bath (control cells 
in a 37C bath) and returned to a 37C incubator for 4 hours. Cells were then 
collected and assayed for the luciferase activity (Promega), protein concentration 
(Pierce), and -galactosidase activity (96).  
 
Cell Survival Assay 
Cell viability was determined using the MTS assay (Promega). HaCaT 
KCs were cultured in 24-well plates and adeno-infected as described previously. 
Twenty-four hours after infection, cells were stressed in a 42C or 37C water 
bath (control) for 1 hour. 
 
HaCaT colony growth transient assay 
HaCaT KCs were seeded in triplicate into 6-well plates (4,500 cells/well) 
and transfected the following day with Effectene (Qiagen; Valencia, CA). Each 
well received 300 ng pCMV-β-gal and either 216 ng of empty pcDNA3.1+ 
(Invitrogen; Carlsbad, CA) and 840 ng pBluescript KS+ or 3000 ng 
pcDNA3.1+TNIP1 sense insert for at least a 20:1 molar difference of pcDNA3.1+ 
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construct to β-gal marker plasmid to provide that any β-gal positive colony 
subsequently counted had derived from a pcDNA-transfected cell. Differences in 
pcDNA3.1+ expression vector amounts standardized copy number of expression 
constructs. Cells were fed 18hrs post-transfection and 3 days later. Seven days 
post-transfection cells were fixed in 2% paraformaldehyde and histochemically 
stained for β-gal. Counting protocols for b-gal positive cells, total cell number, 
and colony number were as described [Zhao JBC 276, p27907] for another NR-
interacting protein. 
 
Constitutive expression of TNIP1 in HaCaT cells 
HaCaT KCs were seeded and transfected with either empty pcDNA3.1+ 
(Invitrogen; Carlsbad, CA) and 840 ng pBluescript KS+ or 3000 ng 
pcDNA3.1+TNIP1 sense or antisense insert containing a neomycin resistant 
cassette at equal copy numbers. Forty-eight hours after transfection, all cultures 
were put under G418 neomycin selection (600 ug/mL) and was replaced during 
every cell feeding days. Cell growth was observed daily.  
 
Statistical analysis 
All data were analyzed using Prism Software version 5 (GraphPad) (La Jolla, 
CA). Student’s t-test was used to compare between paired results. ANOVA with 
Newman Keuls post hoc was used to compare between grouped results, when 
necessary. Statistical significance was defined as p  0.05.  
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Results 
HSPA6 promoter contains known TNIP1-responsive transcription factor binding 
sites 
Since TNIP1 expression results in the reduced activation or activity of 
various transcription factors, we assessed whether the mechanism of TNIP1’s 
repression could be through these factors. As a model for the TNIP1-repression 
of these HSP familes, we further characterized one HSP, HSPA6. We isolated 
and cloned the promoter of HSPA6 3 kb promoter region (-2952 to +48 bp 
relative to the transcriptional start site) to a luciferase reporter gene construct. In 
silico promoter analysis found predicted binding sites for TNIP1-regulated 
transcription factors (Fig 4.1). Between the -647 to +48 bp promoter, no putative 
sites were located. Lengthening the promoter to -1230 bp, two predicted NFκB 
sites were found at -665, and -939 bp. Extending further to -2952 bp, two NFκB 
site (-2830 and -2985bp), two retinoic acid response elements (RARE) (-1625 
and -2419 bp) and five peroxisome proliferator response elements (PPRE)  
(-1580, -1643, -1986, -2604 and -2768 bp).  
 
TNIP1 does not repress HSPA6 through previously characterized pathways 
To localize the TNIP1-responsive region, we generated several 5’-promoter 
truncations using naturally occurring restriction enzyme sites. Transfection 
results show that the “minimal” -70 bp promoter was unaffected by TNIP1. 
Extending the promoter to -647 bp resulted in a ~60% reduction in promoter 
activation. Further lengthening the promoter to -1230 and beyond had Figure 4.1 
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Figure 4.1. In silico analysis of the HSPA6 3 kb promoter searching for 
TNIP1-repressed transcription factors. The promoter isolate was from -2952 to 
+48 bp. KpnI and HindIII were generated using the primers to amplify the 
promoter. BglII, EcoRI and NruI are naturally occurring restriction enzyme sites 
and were use to generate promoter truncation constructs. The triangles, arrows 
and diamonds denote predicted PPRE, RARE and NFκB binding sites, 
respectively.   
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Figure 4.2 
 
 
Figure 4.2. Analysis of the HSPA6 promoter truncation constructs. Diagram 
of the HSPA6 5’ promoter truncation constructs. The triangles, arrows and 
diamonds denote predicted PPRE, RARE and NFκB binding sites, respectively. 
Yellow region indicates the start of the luciferase reporter gene. Graph shown as 
percent response to increased TNIP1 compared to LacZ control. Letters denote 
statistical significance between unstressed cells p<0.05. using ANOVA with 
Newman Keul’s post-hoc. Bars are mean + SEM from n=3, experimental 
triplicates. 
  
 103 
no change in TNIP1 repression compared to the -647 bp promoter, suggesting 
the -647 to -70 bp fragment of the HSPA6 promoter contains a TNIP1-repressible 
element (Fig 4.2).  
 
The TNIP1-repressive region within the HSPA6 promoter is between -216 to -70 
bp 
To narrow down the fragment repressed by TNIP1 within -647 to -70 bp, a 
series of internal promoter deletions was generated deleting ~150 bp regions 
within the -647-luc construct. Four internal deletion constructs were generated: 
ΔA- (-647 to -478 bp), ΔB- (-478 to -346 bp), ΔC- (-346 to -216 bp) and ΔD-luc (-
216 to -70 bp). Only deletion of fragment D (-216 to -70 bp) resulted in significant 
increases in promoter activation (~330%) (Fig 4.3), suggesting TNIP1 sensitive 
regions are within this fragment. Deletion of fragments A, B and C had no 
significant changes in HSPA6 promoter activation. In silico promoter analysis of 
region D (Table 4.2, respectively) showed 6 predicted transcription factor binding 
sites, respectively. More importantly, this region contain no known TNIP1-
repressible transcription factors, indicating that TNIP1 may repress HSPs 
through a novel, possibly not yet characterized TNIP1-repressible factor.  
 
HSPA6 and HSPA1A expression is repressed by TNIP1 in heat stressed 
conditions 
 Since we found that TNIP1 represses HSPA6 in unstressed conditions, we 
tested whether TNIP1 can repress the levels of HSPA6 under heat-stressed 
conditions. We extended our analysis to determine whether HSPA1A is also 
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affected by TNIP1 in stressed conditions. In the control, Ad-LacZ infected cells, 
the stress-induction pattern was similar for both HSPs, however, HSPA6 had a 
greater fold induction. As expected, TNIP1 overexpression reduced basal (t=0) 
expression of both HSPs. The repression under stressed conditions was different 
for HSPA6 and HSPA1A. HSPA6 expression was decreased immediately after 
cell stress and up to 8 hours post heat shock (Fig 4.4, top panel). Interestingly, at 
each timepoint tested, the expression of HSPA6 was ~10-fold less in TNIP1 
overexpressed cells compared to the control infected cells; however, the pattern 
of stress induction and decrease to basal levels was similar, regardless of TNIP1 
overexpression. HSPA1A did not show TNIP1-responsiveness after heat stress 
(Fig 4.4, bottom panel). The differential regulation of these two HSPs could 
suggest a different mechanism for TNIP1 repression. Although TNIP1 represses 
HSPs in basal, unstressed conditions, its control over these HSPs varies under 
stressed conditions.  
 
TNIP1 does not affect cell survival following a short term overexpression 
 To assess the consequence of reduced HSPA6 in stressed conditions in 
response to increased TNIP1, we assessed whether the cell survival of HaCaT 
KCs are compromised after thermal stress. In a similar timeline, TNIP1 or control 
LacZ was increased 24 hours prior to thermal stress, modeling a “short-term” 
overexpression. Adeno-infected cells were heat stressed for 1 hour at 42C, then 
given a 23 hour recovery period at 37C; unstressed cells were incubated for 1 
hour at 42C then given the same recovery conditions. Using the MTS assay to 
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determine the cell viability, we observed that under these conditions increased 
TNIP1 expression had no effect on both unstressed and heat-stressed KCs (Fig 
4.5).  
 
Long term increased TNIP1 expression hinders cell growth 
To determine the effects of altered TNIP1 levels past 24 hours, we 
examined the effect of TNIP1 7-days post overexpression. Using a method 
different than the adenovirus, we transiently co-transfected single cell HaCaT 
keratinocytes with a limiting amount of a β-gal construct as indicator of 
transfection and either an empty vector or one containing the TNIP1 cDNA insert. 
Keratinocytes transfected with TNIP1 yielded more small colonies and fewer 
large colonies compared to those receiving the control vector (Fig 4.6). This 
overall growth reduction is reflected in a significant decrease of the median cells 
per colony for TNIP1 transfected cells (TNIP1, 15/colony; empty vector, 
21/colony).  
To address consequences stemming from chronic altered TNIP1 levels, 
we attempted to generate a HaCaT keratinocyte line stably over-expressing 
TNIP1. Control neor clones were successfully generated from transfection with 
the empty and TNIP1 antisense vector 14-days later. However, HaCaT 
keratinocytes transfected with the TNIP1 cDNA insert did not yield any 
lines. These “long-term” assays demonstrate a negative TNIP1 effect on colony 
expansion and suggest why the long-term growth required for cell line generation 
may not have been possible from TNIP1 over-expressing cells. 
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Figure 4.3 
 
 
Figure 4.3. Analysis of the HSPA6 promoter deletion constructs. Diagram of 
the HSPA6 internal promoter deletions within -647-luc construct. Deletions are 
shown as the dotted line. Graph shown as percent response to increased TNIP1 
compared to LacZ control. Letters denote statistical significance between 
unstressed cells p<0.05. using ANOVA with Newman Keul’s post-hoc. Bars are 
mean + SEM from n=3, experimental triplicates. 
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Table 4.1. List of predicted transcription factor binding sites within the -216 to -70 
bp region of the HSPA6 promoter. 
TF Binding Site Location Score 
p53 tumor suppressor -200 0.933 
Heat shock factors -171 0.97 
Estrogen response elements -160 0.924 
RNA polymerase II transcription factor II B -154 1 
ZF5 POZ domain zinc finger -152 0.92 
E-box binding factors -144 0.935 
AP1, Activating protein 1 -135 1 
MAF and AP1 related factors -134 0.961 
GC-Box factors SP1/GC -124 0.924 
EGR/nerve growth factor induced protein C & related factors -123 0.93 
Pleomorphic adenoma gene -108 0.935 
GC-Box factors SP1/GC -101 0.931 
Heat shock factors -89 0.905 
Mouse Krueppel like factor -71 0.986 
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Figure 4.4 
 
 
 
Figure 4.4. Effect of TNIP1 overexpression on HSPs in heat stressed HaCaT 
KCs. Quantitative PCR of HSPA1A (top panel) and HSPA6 (bottom panel) 
before (t = 0 hour) or after (t = 1, 2, 3, 4, 6 and 8 hours) a 1 hour heat stress at 
42°C. Statistical significance was determined using Student’s t-test, LacZ vs. 
TNIP1: **=p<0.01; *=p<0.05; †=p<0.1; ‡=p<0.15. Bars are mean + SEM from 
experimental triplicates. 
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Figure 4.5 
 
 
Figure 4.5. Effect of “short term” increased TNIP1 levels on HaCaT KCs 
viability and growth. Cell viability analysis of HaCaTs overexpressing LacZ 
(control) or TNIP1 using an adenoviral vector. Cell viability was assessed using 
the MTS assay after a 1 hour heat shock at 42°C, then given a 23 hour recovery 
period at 37°C. 
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Figure 4.6 
 
 
Figure 4.6. Effect of “long term” increased TNIP1 levels on HaCaT KCs 
viability and growth. (Left panel) Long term effect of increased sense TNIP1, or 
control empty vector or antisense TNIP1. Cells per colony were determined 7 
days after TNIP1 overexpression. The box-plot bottom and top edges border the 
25th to 75th percentile, respectively, of colony sizes for each construct; the 
horizontal line across box is at the 50th percentile, the colony median (not the 
mean). Colony sizes for Naf transfection are significantly depressed (*, p<0.05, 
Student’s t-test) compared to empty vector controls. (Right panel) Size 
comparison of early HaCaT keratinocyte colonies developed following single-cell 
transfection with a β-gal marker and empty expression vector (open bars) or 
expression vector with Naf sense cDNA (solid bars).  
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Discussion 
 As observed from results presented in Chapter 2, TNIP1 overexpression 
in HaCaT KCs resulted in reduced expression of several HSP family members, 
including HSPA1A and HSPA6. While TNIP1’s repressive roles in the TNFR and 
NR pathways have been elucidated, these pathways have not been known to 
result in the transcriptional regulation of HSPs. Using HSPA6 as a model for 
other TNIP1-regulated HSP repression, several putative NFκB binding sites, 
PPREs and RAREs were located between the -2952 to -647 bp fragment of the 
HSPA6 promoter. We determined the TNIP1-sensitive region within the promoter 
between -647 to -478 bp and -216 to -70 bp, suggesting the TNFR and NR 
pathways do not play a role in regulating these HSPs. This region lacked any 
known TNIP1-repressed transcription factors even after extending our search to 
include Elk2 (89) and C/EBP (68), the known TNIP1-inhibited downstream 
targets of EGFR and TLR, respectively. These results suggest that the TNIP1-
mediated repression of HSPA6, and likely other HSPs, could be through a novel, 
not yet determined TNIP1-repressible transcription factor. 
 To test the TNIP1-repression of HSPA6 under heat stressed conditions, 
we observed TNIP1 could reduce HSPA6 heat inducibility in addition to its basal 
expression. These results could suggest the mechanism of TNIP1’s repression, 
while not yet fully characterized, could be independent of the thermal stress 
induction. Interestingly, HSPA1A expression was only decreased in unstressed 
conditions. The differential repression of HSPA6 and HSPA1A may suggest that 
TNIP1 regulates these HSPs through different mechanisms under stressed and 
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unstressed conditions. However, a possible mechanism could be that the TNIP1-
repressible transcription factor binds a site next to a heat shock element. When 
HSF is activated, it could displace the TNIP1-repressible transcription factor 
binding the promoter, facilitating the HSF binding the HSE. A similar effect is 
observed in the Gai2 promoter, where SP1 binding is disrupted by activation of 
C/EBP binding an adjacent site (127). Determining any predicted binding site(s) 
near a heat shock element within HSPA1A and matching it with the predicted 
site(s) within the -216 to -70 bp promoter region of HSPA6 could be an avenue to 
determine the specific mechanism of the TNIP1-mediated HSP repression.  
 Since HSPA6 is affected under both unstressed and stressed conditions, 
we tested whether repression of this HSP can affect the cell survival of HaCaT 
cells after a 1 hour, 42C heat shock. The short term cell viability was not 
affected by increased TNIP1 in basal or stressed conditions, suggesting that 
under these conditions, TNIP1 has no overall effect on KC’s stress response. 
Under stressed conditions, however, TNIP1 only reduced HSPA6 expression, not 
HSPA1A, directly after thermal stress and up to an 8 hour time period. Since 
these proteins have similar functions in cell protection, it is possible that the 
redundancy in function between these two HSPs is sufficient to protect HaCaT 
KCs under heat stressed conditions 24 hours post TNIP1 overexpression. The 
effect of increased TNIP1 may affect the HSPs chaperone function, since 
multiple HSPs are decreased. We assessed whether a long term TNIP1 
overexpression could affect the KCs growth under basal conditions. Transient 
overexpression of TNIP1 resulted in a reduction in cell number per colony after 7-
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days. Stably overexpressing TNIP1 resulted in no colony growth after 2 weeks. 
The decrease in HSP expression levels could have led to the increase in KC cell 
death. Prior work where the HSPA1A gene was deleted in a mouse model shows 
a change in tissue physiology and function in unstressed cells (128), indicating its 
importance not only in stress protection, but as a molecular chaperone. The 
decrease of various HSPs by TNIP1 could affect the normal structure and 
proliferation of keratinocytes, possibly resulting in the observed decrease in cell 
growth. Taken together, these results suggest that the chronic overexposure to 
TNIP1 negatively affects cell growth under basal, unstressed conditions. The 
decreased levels of HSPs and the resulting reduced chaperone ability may 
impair these cells to properly synthesize new proteins required for cell growth 
and proliferation.  
 In this chapter, we found that the TNIP1-mediated repression of HSPA6 is 
not through known TNIP1-repressed transcription factors, but likely a novel, not 
yet characterized mechanism. Additionally, the effect of TNIP1 on HSPs varies in 
heat stressed conditions, where only HSPA6, not HSPA1A, expression was 
reduced. The overall cell consequences of increased TNIP1 were observed in a 
chronic overexpression of TNIP1, resulting in decreased KC growth and 
proliferation.  
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Chapter 5 
Summary, conclusions and future directions 
Summary and conclusions  
Initial work on the TNFα-induced protein 3 (TNFAIP3)-interacting protein 1 
(TNIP1) started in our laboratory while searching for novel NR coregulators in the 
skin. Previous efforts characterized TNIP1’s role as an agonist-bound NR 
corepressor, specifically of PPAR and RARs (24, 25), and determined TNIP1’s 
transcriptional regulation and start sites (see Appendix 1 for TSS results) (44, 
129). Researchers from other laboratories found TNIP1 to reduce the activation 
and nuclear translocation of several transcription factors, including NF-kB (see 
(41) for a current review). Overall, the resulting effect of TNIP1 can be 
generalized as the direct or indirect repression of transcription factor activity or 
activation.  
These factors and their associated pathways, in part, regulate several 
biological processes, including inflammatory diseases and KC growth. Indeed, 
TNIP1 has been implicated in several diseases, including psoriasis, a disease 
characterized by KC hyperproliferation and incomplete differentiation (34, 52). 
Altered TNIP1 sequence and increased expression levels were observed in this 
disease, suggesting it may play a role in regulating KC function. Although 
TNIP1’s transcriptional regulation, repressive role in several pathways, and 
association in various biological processes have been established, the specific 
genes regulated by TNIP1 and the overall cellular outcomes of increased TNIP1 
expression have not yet been determined. 
 115 
The work in this thesis aimed to determine the genes and pathways 
regulated by TNIP1 as well as characterize the consequences of transient 
increased expression of TNIP1 in KCs. The studies described validated TNIP1’s 
role in regulating the NR pathways, inflammatory diseases, and cell death. 
Several novel TNIP1-regulated pathways and genes were also found, including 
the cell stress response and repression of several HSPs. Proteins within this 
family, which have been implicated in psoriasis and cell death, were reduced as 
much as 20-fold in response to increased TNIP1. The reduced expression of 
these HSPs in the HaCaT KCs, which are an immortalized, but non-tumorigenic 
KC cell line, was validated by using normal human epidermal KCs. Interestingly, 
in addition to reducing HSP expression in differentiated KCs, TNIP1 
overexpression in the normal human epidermal KCs resulted in blocking the 
induction of involucrin, a KC differentiation marker, indicating that TNIP1 could 
modulate KC differentiation.  
To examine TNIP1’s effect on cultured KCs, we assessed the overall the 
growth of KCs following increased TNIP1 levels. TNIP1 had no effect on cell 
growth in normal or heat stressed conditions 24 hours after transient 
overexpression; long term (7 day) transient overexpression of TNIP1 led to 
decreased cell colony size and number. Attempting to generate a chronic, stably 
overexpressing TNIP1 KC line resulted in complete loss of cell growth, 
suggesting that TNIP1 may play key roles in KC biology, possibly through 
repression of HSP chaperone expression.  
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HSPA6 was used as a model to determine the possible mechanism of 
how TNIP1 reduces HSP expression. HSPA6 was the gene reduced the most 
after TNIP1 overexpression. We hypothesized that the TNIP1-mediated 
repression was through the known, well characterized TNIP1-repressed 
transcription factors PPAR, RAR or NF-kB. While several predicted binding sites 
were found within the -3 kb promoter, the specific region responsive to TNIP1 (-
216 to -70 bp) lacked these predicted binding sites. In addition to these 
transcription factors, two others have been described to be repressed by TNIP1 
through upstream regulatory proteins, Elk-2 and C/EBP. Unfortunately, this 
promoter region also lacks predicted binding sites for these factors. A possible 
pathway involved in the HSP repression could be the EGFR-ERK2 pathway. The 
repression of Elk-2 by TNIP1 is mediated by blocking EGFR-induced ERK2 
nuclear translocation. In silico promoter analysis of the -216 to -70 bp region 
suggests some of the top predicted sites could be ERK2 activated, such as 
EGR1, KLF and E-box binding transcription factors. However, these sites and 
their associated transcription factors are not known regulators HSPs expression. 
An in depth analysis to examine if these factors regulate HSPA6 could be 
assessed for future experiments. 
A second possibility is that TNIP1 may reduce the expression of the 
transcription factor(s) regulating the transcription of HSPA6. Searching the list of 
predicted transcription factor sites within this fragment (Table 4.2), four genes 
encoding transcription factors whose expression was reduced by TNIP1 
overexpression were found. AP1 heterodimer protein subunits (fosB, c-fos and c-
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jun) and early growth response 1 (EGR1) mRNA expression was decreased. It is 
unlikely that AP1 is involved in the TNIP1 repression because a separate region 
of the promoter, which is also contains an AP1 site, is not responsive to TNIP1. It 
is possible that EGR1 protein expression is reduced after TNIP1 overexpression, 
causing a reduction in HSPA6 transcription. This presupposes that EGR1 
transcriptionally regulates the expression of HSPs, which has not yet been 
characterized.  
To determine if an ERK2-mediated transcription factor (EGR1, KLF or E-
box binding transcription factors) repressed by TNIP1 could be contributing to the 
reduced HSP expression, an extensive examination would need to be done to (1) 
establish if ERK2 activation results in increased endogenous HSP expression, 
(2) determine whether ERK2 stimulation can activate the -216 to -70 bp promoter 
region of HSPA6, (3) test if these factors bind the promoter, and (4) characterize 
if TNIP1 can repress this factor. Since the aims of this research were to 
determine the pathways affected by and cellular outcomes due to increased 
TNIP1, the work presented in this thesis met this goal. 
Along with Gomez-Sucerquia (81), a novel finding from this research was 
the observation that HSPA6 protein was readily found in unstressed all cell types 
examined (Ramirez et al submitted), whereas other laboratories noted little to no 
basal expression in varying cell types including HaCaT KCs (74, 82, 83, 112, 
115, 130, 131). The antibody (ADI-SPA-754) used was previously characterized 
by (82) to be highly specific to HSPA6, suggesting that the band observed was 
HSPA6. A possible explanation for this discrepancy could be the DMEM/F12 
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media used to grow the cells. The media used to culture all the cells contains a 
3:1 ratio of DMEM to Ham’s F12 (HaCaT, SCC13, MCF7, HeLa, HepG2 and 
dermal fibroblasts) or were supplemented with non-essential amino acids (HT29 
and Caco2). Modifying the ingredients of the cell culture media has led to 
increased expression of HSPs (117, 118). Additionally, (81) supplemented the 
culture media with non-essential amino acids. HSPA6 protein expression was 
observed in untreated cells. The basal expression of HSPA6 could be sensitive 
not only to changes in cell density (83), but also cell culture media components. 
The additional supplement to our HaCaT media could explain the difference in 
basal HSPA6 expression level compared to (74).  
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Future directions 
The studies described in this thesis open up a number of possibilities in 
characterizing the role TNIP1 plays not only in regulating HSPs, but in normal 
and diseased KC biology. With respect to the TNIP1-mediated repression of 
HSPs, this work suggests TNIP1 could alter the chaperone function, but not the 
immediate stress-protective role, of HSPs. Interestingly, the reduction in KC cell 
growth was only observed in long-term TNIP1 overexpression. It would be 
interesting to examine the expression levels of these HSPs after chronic TNIP1 
exposure to assess whether the reduced levels of HSPs could contribute to the 
reduced cell viability. 
 Further work to elucidate the mechanism of the HSP repression by TNIP1 
is necessary. To date, the work described examined whether transcription factors 
PPAR, RAR or NF-kB were involved in the repression of HSPs. Our work 
indicates that these factors were not responsible for the reduced expression of 
HSPs. This may suggest a new factor, and possibly pathway, is repressed by 
TNIP1 to block the transcription of these genes. While a TNIP1-responsive 
fragment within the HSPA6 promoter was localized, the specific element within it 
was not determined. Site-directed mutagenesis of the top-scoring sites could be 
done to elucidate the specific transcription factor involved in the repression of 
HSPA6 and possibly other HSPs. In addition to the TNIP1-mediated repression 
of HSPA6, putative transcription factor binding sites and a ~150 bp region within 
the central region of the promoter was responsive to a yet uncharacterized 
repressive factor(s) in normal, basal conditions. Further investigation is needed 
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to determine the factor(s) contributing to the reduced expression of HSPA6 in 
unstressed conditions.  
While the association between TNIP1 and KCs proliferation and 
differentiation was characterized in this research, the specific role it could play in 
inflammatory diseases, such as psoriasis, has not yet been determined. In the 
TNIP1 microarray, expression of a number of inflammatory cytokines was 
reduced; most notably IL-6 was decreased 10-fold. This result was only 
determined at one timepoint, 24 hours post TNIP1 overexpression. To determine 
TNIP1’s role in regulating these cytokines, a time-course study examining the 
varied expression level of these, and other proteins, is necessary. Studying the 
changes of these genes’ expression could determine a mechanism for how 
TNIP1 affects these diseases. 
A shortcoming to the research presented here was most the work 
presented was performed in cultured normal or immortalized monolayer of KCs. 
While these cell lines retain the differentiation properties, they are still not 
stratified KCs such as found in skin. A possible avenue for research to mimic the 
stratification of KCs into layers is to generate a KC organotypic model (132). 
These organotypic cultures recapitulate the biochemical markers of differentiating 
KCs resulting in cornification of the cultured cells. In these cultures, TNIP1 
expression can be increased and the thickness of the organotypic layer 
quantified. In this approach, a direct effect of KC proliferation and differentiation 
can be examined in a manner where the level of TNIP1 overexpression could be 
controlled. More importantly, the effect of increasing TNIP1 could be assessed in 
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a “dose-dependent” fashion. Conversely, to assess the impact of TNIP1 in whole 
animal models, an adenoviral gene transfer can be performed in normal mice 
(65, 66). Although this method was previously performed by the Beyaert 
laboratory to exogenously express TNIP1, the effect on KC homeostasis was not 
assessed.  
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Appendix 1 
TNIP1 protein expression up to 96 hours post adeno-infection 
 
  
 This experiment was performed by Carmen Zhang (experiment # 158) 
before the microarray was performed. TNIP1 -overexpressed HaCaT cells were 
collected at 24-, 48-, 72-, or 96-hours post infection. TNIP1 expression was 
increased up to the 96-hour timepoint.  
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APPENDIX 2 
Microarray data from TNIP1 overexpression in HaCaT KCs 
SYMBOL ratio t/w ILMN_GENE DEFINITION 
HSPA6 0.05 HSPA6 
Homo sapiens heat shock 70kDa protein 6 
(HSP70B') (HSPA6), mRNA. 
IL6 0.1 IL6 
Homo sapiens interleukin 6 (interferon, beta 2) 
(IL6), mRNA. 
FOSB 0.12 FOSB 
Homo sapiens FBJ murine osteosarcoma viral 
oncogene homolog B (FOSB), mRNA. 
ZC3HAV1 0.16 ZC3HAV1 
Homo sapiens zinc finger CCCH-type, antiviral 1 
(ZC3HAV1), transcript variant 2, mRNA. 
EGR1 0.18 EGR1 
Homo sapiens early growth response 1 (EGR1), 
mRNA. 
DNAJB1 0.2 DNAJB1 
Homo sapiens DnaJ (Hsp40) homolog, 
subfamily B, member 1 (DNAJB1), mRNA. 
LOC652878 0.2 LOC652878 
PREDICTED: Homo sapiens similar to heat 
shock 70kDa protein 6 (HSP70B) (LOC652878), 
mRNA. 
ARID5B 0.21 ARID5B 
Homo sapiens AT rich interactive domain 5B 
(MRF1-like) (ARID5B), mRNA. 
HERC5 0.23 HERC5 
Homo sapiens hect domain and RLD 5 (HERC5), 
mRNA. 
MX1 0.24 MX1 
Homo sapiens myxovirus (influenza virus) 
resistance 1, interferon-inducible protein p78 
(mouse) (MX1), mRNA. 
ISG20 0.25 ISG20 
Homo sapiens interferon stimulated 
exonuclease gene 20kDa (ISG20), mRNA. 
ACTR10 0.26 ACTR10 
Homo sapiens actin-related protein 10 
homolog (S. cerevisiae) (ACTR10), mRNA. 
MYH3 0.26 MYH3 
Homo sapiens myosin, heavy polypeptide 3, 
skeletal muscle, embryonic (MYH3), mRNA. 
IFI27 0.27 IFI27 
Homo sapiens interferon, alpha-inducible 
protein 27 (IFI27), mRNA. 
AXUD1 0.28 AXUD1 
Homo sapiens AXIN1 up-regulated 1 (AXUD1), 
mRNA. 
DUSP1 0.28 DUSP1 
Homo sapiens dual specificity phosphatase 1 
(DUSP1), mRNA. 
IFIT2 0.28 IFIT2 
Homo sapiens interferon-induced protein with 
tetratricopeptide repeats 2 (IFIT2), mRNA. 
SGK 0.28 SGK 
Homo sapiens serum/glucocorticoid regulated 
kinase (SGK), mRNA. 
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0.28 HS.579631 
AGENCOURT_10229596 NIH_MGC_141 Homo 
sapiens cDNA clone IMAGE:6563923 5, mRNA 
sequence 
CYR61 0.29 CYR61 
Homo sapiens cysteine-rich, angiogenic 
inducer, 61 (CYR61), mRNA. 
CLCF1 0.3 CLCF1 
Homo sapiens cardiotrophin-like cytokine 
factor 1 (CLCF1), mRNA. 
IFIT3 0.3 IFIT3 
Homo sapiens interferon-induced protein with 
tetratricopeptide repeats 3 (IFIT3), mRNA. 
FLJ31875 0.31 FLJ31875 
Homo sapiens hypothetical protein FLJ31875 
(FLJ31875), mRNA. 
HSPA1B 0.31 HSPA1B 
Homo sapiens heat shock 70kDa protein 1B 
(HSPA1B), mRNA. 
JUN 0.31 JUN Homo sapiens jun oncogene (JUN), mRNA. 
OASL 0.31 OASL 
Homo sapiens 2'-5'-oligoadenylate synthetase-
like (OASL), transcript variant 1, mRNA. 
PPP1R15A 0.31 PPP1R15A 
Homo sapiens protein phosphatase 1, 
regulatory (inhibitor) subunit 15A (PPP1R15A), 
mRNA. 
ARID3B 0.32 ARID3B 
Homo sapiens AT rich interactive domain 3B 
(BRIGHT- like) (ARID3B), mRNA. 
CPEB3 0.33 CPEB3 
Homo sapiens cytoplasmic polyadenylation 
element binding protein 3 (CPEB3), mRNA. 
FOS 0.33 FOS 
Homo sapiens v-fos FBJ murine osteosarcoma 
viral oncogene homolog (FOS), mRNA. 
HSPA1A 0.33 HSPA1A 
Homo sapiens heat shock 70kDa protein 1A 
(HSPA1A), mRNA. 
MX2 0.33 MX2 
Homo sapiens myxovirus (influenza virus) 
resistance 2 (mouse) (MX2), mRNA. 
TRIB1 0.33 TRIB1 
Homo sapiens tribbles homolog 1 (Drosophila) 
(TRIB1), mRNA. 
ZFP36 0.33 ZFP36 
Homo sapiens zinc finger protein 36, C3H type, 
homolog (mouse) (ZFP36), mRNA. 
USP36 0.34 USP36 
Homo sapiens ubiquitin specific peptidase 36 
(USP36), mRNA. 
DUSP5 0.35 DUSP5 
Homo sapiens dual specificity phosphatase 5 
(DUSP5), mRNA. 
ERRFI1 0.35 ERRFI1 
Homo sapiens ERBB receptor feedback 
inhibitor 1 (ERRFI1), mRNA. 
IFIT1 0.35 IFIT1 
Homo sapiens interferon-induced protein with 
tetratricopeptide repeats 1 (IFIT1), transcript 
variant 2, mRNA. 
EDN1 0.36 EDN1 Homo sapiens endothelin 1 (EDN1), mRNA. 
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G1P3 0.36 G1P3 
Homo sapiens interferon, alpha-inducible 
protein (clone IFI-6-16) (G1P3), transcript 
variant 1, mRNA. 
RARRES3 0.36 RARRES3 
Homo sapiens retinoic acid receptor responder 
(tazarotene induced) 3 (RARRES3), mRNA. 
RGC32 0.36 RGC32 
Homo sapiens response gene to complement 
32 (RGC32), mRNA. 
BCL3 0.37 BCL3 
Homo sapiens B-cell CLL/lymphoma 3 (BCL3), 
mRNA. 
HERC6 0.37 HERC6 
Homo sapiens hect domain and RLD 6 (HERC6), 
transcript variant 4, mRNA. 
IFIH1 0.37 IFIH1 
Homo sapiens interferon induced with helicase 
C domain 1 (IFIH1), mRNA. 
PIM1 0.37 PIM1 Homo sapiens pim-1 oncogene (PIM1), mRNA. 
WARS 0.37 WARS 
Homo sapiens tryptophanyl-tRNA synthetase 
(WARS), transcript variant 1, mRNA. 
ABTB2 0.38 ABTB2 
Homo sapiens ankyrin repeat and BTB (POZ) 
domain containing 2 (ABTB2), mRNA. 
PTGS2 0.38 PTGS2 
Homo sapiens prostaglandin-endoperoxide 
synthase 2 (prostaglandin G/H synthase and 
cyclooxygenase) (PTGS2), mRNA. 
 
0.38 HS.263832 
BX096516 Soares_NhHMPu_S1 Homo sapiens 
cDNA clone IMAGp998J135216, mRNA 
sequence 
BHLHB2 0.39 BHLHB2 
Homo sapiens basic helix-loop-helix domain 
containing, class B, 2 (BHLHB2), mRNA. 
ISG15 0.39 ISG15 
Homo sapiens ISG15 ubiquitin-like modifier 
(ISG15), mRNA. 
OAS2 0.39 OAS2 
Homo sapiens 2'-5'-oligoadenylate synthetase 
2, 69/71kDa (OAS2), transcript variant 3, 
mRNA. 
RN7SK 0.39 RN7SK 
Homo sapiens RNA, 7SK, nuclear (RN7SK) on 
chromosome 6. 
ATF3 0.4 ATF3 
Homo sapiens activating transcription factor 3 
(ATF3), transcript variant 4, mRNA. 
CTGF 0.4 CTGF 
Homo sapiens connective tissue growth factor 
(CTGF), mRNA. 
ELF3 0.4 ELF3 
Homo sapiens E74-like factor 3 (ets domain 
transcription factor, epithelial-specific ) (ELF3), 
mRNA. 
HMFN0839 0.4 HMFN0839 
Homo sapiens lung cancer metastasis-
associated protein (MAG1), mRNA. 
MIDN 0.4 MIDN Homo sapiens midnolin (MIDN), mRNA. 
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PRICKLE1 0.4 PRICKLE1 
Homo sapiens prickle homolog 1 (Drosophila) 
(PRICKLE1), mRNA. 
STX3A 0.4 STX3A Homo sapiens syntaxin 3 (STX3), mRNA. 
TMEM2 0.4 TMEM2 
Homo sapiens transmembrane protein 2 
(TMEM2), mRNA. 
CITED2 0.41 CITED2 
Homo sapiens Cbp/p300-interacting 
transactivator, with Glu/Asp-rich carboxy-
terminal domain, 2 (CITED2), mRNA. 
LATS2 0.41 LATS2 
Homo sapiens LATS, large tumor suppressor, 
homolog 2 (Drosophila) (LATS2), mRNA. 
UGCG 0.41 UGCG 
Homo sapiens UDP-glucose ceramide 
glucosyltransferase (UGCG), mRNA. 
 
0.41 HS.543887 
AGENCOURT_14535501 NIH_MGC_191 Homo 
sapiens cDNA clone IMAGE:30415823 5, mRNA 
sequence 
BAG3 0.42 BAG3 
Homo sapiens BCL2-associated athanogene 3 
(BAG3), mRNA. 
CCL5 0.42 CCL5 
Homo sapiens chemokine (C-C motif) ligand 5 
(CCL5), mRNA. 
SP110 0.42 SP110 
Homo sapiens SP110 nuclear body protein 
(SP110), transcript variant c, mRNA. 
XAF1 0.42 XAF1 
Homo sapiens XIAP associated factor-1 (XAF1), 
transcript variant 2, mRNA. 
CD55 0.43 CD55 
Homo sapiens CD55 molecule, decay 
accelerating factor for complement (Cromer 
blood group) (CD55), mRNA. 
DCUN1D3 0.43 DCUN1D3 
Homo sapiens DCN1, defective in cullin 
neddylation 1, domain containing 3 (S. 
cerevisiae) (DCUN1D3), mRNA. 
EPSTI1 0.43 EPSTI1 
Homo sapiens epithelial stromal interaction 1 
(breast) (EPSTI1), transcript variant 2, mRNA. 
FOXO3A 0.43 FOXO3A 
Homo sapiens forkhead box O3A (FOXO3A), 
transcript variant 2, mRNA. 
GLTSCR1 0.43 GLTSCR1 
Homo sapiens glioma tumor suppressor 
candidate region gene 1 (GLTSCR1), mRNA. 
LGP2 0.43 LGP2 
Homo sapiens likely ortholog of mouse 
D11lgp2 (LGP2), mRNA. 
LOC387841 0.43 LOC387841 
PREDICTED: Homo sapiens similar to ribosomal 
protein L13a, transcript variant 2 (LOC387841), 
mRNA. 
CCRN4L 0.44 CCRN4L 
Homo sapiens CCR4 carbon catabolite 
repression 4-like (S. cerevisiae) (CCRN4L), 
mRNA. 
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FHL2 0.44 FHL2 
Homo sapiens four and a half LIM domains 2 
(FHL2), transcript variant 1, mRNA. 
IFI6 0.44 IFI6 
Homo sapiens interferon, alpha-inducible 
protein 6 (IFI6), transcript variant 2, mRNA. 
PARP14 0.44 PARP14 
Homo sapiens poly (ADP-ribose) polymerase 
family, member 14 (PARP14), mRNA. 
BCL6 0.45 BCL6 
Homo sapiens B-cell CLL/lymphoma 6 (zinc 
finger protein 51) (BCL6), transcript variant 2, 
mRNA. 
BTG1 0.45 BTG1 
Homo sapiens B-cell translocation gene 1, anti-
proliferative (BTG1), mRNA. 
DKK4 0.45 DKK4 
Homo sapiens dickkopf homolog 4 (Xenopus 
laevis) (DKK4), mRNA. 
FOXA1 0.45 FOXA1 
Homo sapiens forkhead box A1 (FOXA1), 
mRNA. 
IFITM1 0.45 IFITM1 
Homo sapiens interferon induced 
transmembrane protein 1 (9-27) (IFITM1), 
mRNA. 
RAB30 0.45 RAB30 
Homo sapiens RAB30, member RAS oncogene 
family (RAB30), mRNA. 
SAMD9L 0.45 SAMD9L 
Homo sapiens sterile alpha motif domain 
containing 9-like (SAMD9L), mRNA. 
TXNRD1 0.45 TXNRD1 
Homo sapiens thioredoxin reductase 1 
(TXNRD1), transcript variant 4, mRNA. 
YTHDC1 0.45 YTHDC1 
Homo sapiens YTH domain containing 1 
(YTHDC1), transcript variant 1, mRNA. 
C6orf128 0.46 C6ORF128 
Homo sapiens chromosome 6 open reading 
frame 128 (C6orf128), mRNA. 
IFI44 0.46 IFI44 
Homo sapiens interferon-induced protein 44 
(IFI44), mRNA. 
IL29 0.46 IL29 
Homo sapiens interleukin 29 (interferon, 
lambda 1) (IL29), mRNA. 
PRKCH 0.46 PRKCH 
Homo sapiens protein kinase C, eta (PRKCH), 
mRNA. 
STX11 0.46 STX11 Homo sapiens syntaxin 11 (STX11), mRNA. 
TRIM26 0.46 TRIM26 
Homo sapiens tripartite motif-containing 26 
(TRIM26), mRNA. 
DUSP19 0.47 DUSP19 
Homo sapiens dual specificity phosphatase 19 
(DUSP19), mRNA. 
FAM46A 0.47 FAM46A 
Homo sapiens family with sequence similarity 
46, member A (FAM46A), mRNA. 
IRF7 0.47 IRF7 
Homo sapiens interferon regulatory factor 7 
(IRF7), transcript variant d, mRNA. 
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KLF6 0.47 KLF6 
Homo sapiens Kruppel-like factor 6 (KLF6), 
transcript variant 2, mRNA. 
S100A2 0.47 S100A2 
Homo sapiens S100 calcium binding protein A2 
(S100A2), mRNA. 
TMEM27 0.47 TMEM27 
Homo sapiens transmembrane protein 27 
(TMEM27), mRNA. 
TSC22D1 0.47 TSC22D1 
Homo sapiens TSC22 domain family, member 1 
(TSC22D1), transcript variant 1, mRNA. 
ZNF342 0.47 ZNF342 
Homo sapiens zinc finger protein 342 
(ZNF342), mRNA. 
ADM 0.48 ADM Homo sapiens adrenomedullin (ADM), mRNA. 
ANTXR2 0.48 ANTXR2 
Homo sapiens anthrax toxin receptor 2 
(ANTXR2), mRNA. 
CCNL1 0.48 CCNL1 Homo sapiens cyclin L1 (CCNL1), mRNA. 
EFNB2 0.48 EFNB2 Homo sapiens ephrin-B2 (EFNB2), mRNA. 
GPRC5A 0.48 GPRC5A 
Homo sapiens G protein-coupled receptor, 
family C, group 5, member A (GPRC5A), mRNA. 
HS3ST2 0.48 HS3ST2 
Homo sapiens heparan sulfate (glucosamine) 
3-O-sulfotransferase 2 (HS3ST2), mRNA. 
MAF 0.48 MAF 
Homo sapiens v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog (avian) 
(MAF), transcript variant 1, mRNA. 
SPEN 0.48 SPEN 
Homo sapiens spen homolog, transcriptional 
regulator (Drosophila) (SPEN), mRNA. 
 
0.48 HS.572444 
Homo sapiens cDNA: FLJ21679 fis, clone 
COL09221 
AHR 0.49 AHR 
Homo sapiens aryl hydrocarbon receptor 
(AHR), mRNA. 
C18orf8 0.49 C18ORF8 
Homo sapiens chromosome 18 open reading 
frame 8 (C18orf8), mRNA. 
CPEB2 0.49 CPEB2 
PREDICTED: Homo sapiens cytoplasmic 
polyadenylation element binding protein 2, 
transcript variant 2 (CPEB2), mRNA. 
DDX58 0.49 DDX58 
Homo sapiens DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 58 (DDX58), mRNA. 
EIF2C2 0.49 EIF2C2 
Homo sapiens eukaryotic translation initiation 
factor 2C, 2 (EIF2C2), mRNA. 
F2RL1 0.49 F2RL1 
Homo sapiens coagulation factor II (thrombin) 
receptor-like 1 (F2RL1), mRNA. 
IFITM2 0.49 IFITM2 
Homo sapiens interferon induced 
transmembrane protein 2 (1-8D) (IFITM2), 
mRNA. 
LDLR 0.49 LDLR Homo sapiens low density lipoprotein receptor 
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(familial hypercholesterolemia) (LDLR), mRNA. 
PLEKHC1 0.49 PLEKHC1 
Homo sapiens pleckstrin homology domain 
containing, family C (with FERM domain) 
member 1 (PLEKHC1), mRNA. 
RNMT 0.49 RNMT 
Homo sapiens RNA (guanine-7-) 
methyltransferase (RNMT), mRNA. 
SP100 0.49 SP100 
Homo sapiens SP100 nuclear antigen (SP100), 
transcript variant 1, mRNA. 
TRIM21 0.49 TRIM21 
Homo sapiens tripartite motif-containing 21 
(TRIM21), mRNA. 
C15orf39 0.5 C15ORF39 
Homo sapiens chromosome 15 open reading 
frame 39 (C15orf39), mRNA. 
C1orf77 0.5 C1ORF77 
Homo sapiens chromosome 1 open reading 
frame 77 (C1orf77), mRNA. 
CDKN1A 0.5 CDKN1A 
Homo sapiens cyclin-dependent kinase 
inhibitor 1A (p21, Cip1) (CDKN1A), transcript 
variant 2, mRNA. 
DDIT3 0.5 DDIT3 
Homo sapiens DNA-damage-inducible 
transcript 3 (DDIT3), mRNA. 
DNAJA1 0.5 DNAJA1 
Homo sapiens DnaJ (Hsp40) homolog, 
subfamily A, member 1 (DNAJA1), mRNA. 
FBXO32 0.5 FBXO32 
Homo sapiens F-box protein 32 (FBXO32), 
transcript variant 2, mRNA. 
IRS2 0.5 IRS2 
Homo sapiens insulin receptor substrate 2 
(IRS2), mRNA. 
NFKBIA 0.5 NFKBIA 
Homo sapiens nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, 
alpha (NFKBIA), mRNA. 
PARP12 0.5 PARP12 
Homo sapiens poly (ADP-ribose) polymerase 
family, member 12 (PARP12), mRNA. 
 
0.5 HS.495542 
PREDICTED: Homo sapiens hypothetical gene 
supported by BC027323 (LOC441477), mRNA 
LTB4R2 2.04 LTB4R2 
Homo sapiens leukotriene B4 receptor 2 
(LTB4R2), mRNA. 
RNASE7 2.07 RNASE7 
Homo sapiens ribonuclease, RNase A family, 7 
(RNASE7), mRNA. 
UAP1L1 2.14 UAP1L1 
Homo sapiens UDP-N-acteylglucosamine 
pyrophosphorylase 1-like 1 (UAP1L1), mRNA. 
MAPK13 5.63 MAPK13 
Homo sapiens mitogen-activated protein 
kinase 13 (MAPK13), mRNA. 
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Appendix 3 
Protocol for making pGL4.1 HSPA6 5’ truncation constructs 
 The HSPA6 -2962 to +48 (herein called 3kb) promoter fragment was 
PCR’ed from human genomic placental DNA (BD Biosciences cat# 
636401) 
 PCR primers sequences 
o Forward: gatgCTCGAGtttggctgtgtccccacccgaatatca (KpnI 
underlined) 
o Reverse: GGCTGAAGCTTCTTGTCGGATGCTGGA (HindIII 
underlined) 
 PCR conditions using Roche High Fidelity PCR master kit 
o 94C for 3 minutes 
o 94C for 30 seconds 
o 62C for 30 seconds 32x 
o 68C for 3.5 minutes 
o 68C for 5 minutes 
 HSPA6 3kb promoter was inserted using KpnI and HindIII sites into the 
pGL4.10 vector. 
 To generate HSPA6 5’-truncation constructs, pGL4.1 HSPA6 3kb 
construct was digested with KpnI (left) and a second restriction site (BglII 
for -1230; EcoRI for -647; NruI for -70) to remove the upstream DNA 
fragments.  DNA was blunt ended, gel extracted, and ligated.   
 HSPA6 3kb sequence restriction enzyme sites  
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1 site only 
 
2 sites only 
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Biotech center sequenced HSPA6 promoter (-2962 to +48) 
 -2962 (introduced KpnI site) to -1231 bp 
O TCATCTTGAATTCCCACAACACATGGGAGGGACCCAGTGGAAGGTAACTGA
ATCATGGGGCAGGTCTTTCCCATGCTGTTCTTGTGATAGTGAATAAGTCTCA
TGAGATCTGATGGTTTTAAAAAGGGGAGTTTCCCTGCACAAGCTCTCTCTTC
TCTTGTTTGCCACCATGTGAGACATGACTTTCACCTTTTGCCATGATTGTGA
GGCCTCCCAGCCACGTGGAACTGTAAGTCCATTAAACCTCTTTCTTTTGTAA
ATTGCCCCGTCTCAGGTATGTCTTTATTAGCAGTGTGAGAATGGGCTAACAC
ATACAACTTGCTTTTTTTTTGTACTCAATATTGAGTCGTGAGCTTTGCACCAC
ATTAGAATGTCTATTTAAGTCATTACTTTAAGGTCGGTTCTATTTTTAAAGCTA
CTCAAACTAAGCTACTAAACATAAGTGGATATATTTAAGTGTATGTATAAAAT
TTATACTAGGCCAGCTGCAGTGGCTCATGCCTGTAATCCCAAAGCTGTGGA
AGGTAGAGGTGGGACTGATTGAGGCCACGAGTTCAAGGCTGCAGTGAGCT
GTGATTGCATCACTGTACTCCAGCCTGAGGGACAGAGCAGGAACCAGAAAA
AAATAAAATAAAAAGAAACAAACAAAAAAACCCCCAACAACCCTACAGTGGC
TCTTTTAGAAAAAACAAACAAACAAAACCAAAACTGTACTGCATGCATAAGCT
CCCCTATGCTATGTTTGAACCACTCTGAAGAGATCAATTAAAAAGAAGTGAG
TGATATTGGAAGCATGCCTCTGTGATGCTGTGGTAACATTCATAGGCTGCGT
TAGGGCTATGCCTGTAACTCTTGGAGATGAGTGGGTAAGTGGGGTTTTGAG
GTGGCTGGGGGCTGGAAGAGAAGGTTGGAGGAGCCCACACAAGACAGCC
CCTTAACACGCCGGGGCACAGAACCCCAGGCTGGGCCAACTTTTCCCTGCT
GAGGTGAAGACCCGTCTCTTGCAGGCCGTTGGCAAATGTCTTGACTCTGGC
ATCCAGGTGTGACCAGCTTAGACCCTGAGAGTGAGTGAATTTAAAGTTGAC
AGCTTCTTTCCCTTTTGGAATTATGAAATAGGTTACTTCTTTTCAAGGACAGT
TTGATTTTCCACTGTGTAAGTCATATATTGCACATTTCTTTAAACATTCCCTTT
TTTCCTGAACTGATCACCTTACCAGTACGGCTGATCCTCTCAAGCAGCAAAC
TCTACCAGCTGTCACTGGTGCTCTCGGAGAGACGATTAACCAAGGAACCCA
GCCCGGGAACAGTACTGACCTCTACTTCTGGACTCCTGCCTCCCTCTTAAAA
AGTCCCTTGAACTTCCTAGTGGGTTCTAACCTGTCAAAGGAGAAAATAGCCA
TCTATGGAGTAAGGGTTTTTAGTTTCTCTTTTTACAAATGGAAGTTTCCTCTG
AATCAGGCAAGTAACGTTAAATAGAAGCCAACTTTTAAGTTTCTCTAACACAC
TGCTAAATTGTAACACCAGACTGTACCACATACTCTCCAGCTGCCAGCTATT
GCAGTTGCCATCCTTGTTACTATAGTGGTGAGTATCTCTGCCTGTCATGCGT
GAGAGAGGGGGTCGATTCCCCGACGGGGAGGTCACGGGAAATTGTGTGAG
GATTTTGTCAACCTTCAGAAGTCTCAGAAATGTCTCCTTGTTTTGGCTTTCAG
CGGAAATCCGAACGCCAGCA 
 
 -1230 (Existing BglII site) to -648 bp 
O GATCTGAATGGAATGTTCTGGATTGAAGAAAGTGGGAAATGGCCTCAATTCA
CAAAGTCACAACCTGATAAAAACCAGTGTGACTTTACTGCCCAGTGAACCCA
TCTCGTCCTCCAGCCTTTAGGAGGTAGGTTGGACTGGAGCCTGCAGTAGTT
TACTCTCCACCTGAGTCCTGGTCTCCAGCTGGGAACCCACTTAGGCCATAG
AGAAAAACGCACACTGTGCCTCTCCACCGGGCCTCTGGAGACGAGGCTCC
TCGGGGATACAAACAGTGGGGAGAACATGAGGGACATCCCGACCGTACTC
TGCGTCCTCCTTTCCCAGGTGTTGCGTTCTCTCTTGGGCTGAGTGGCGAGG
TCTCTCCCGAGTCCCAGGGCCACAGTGCAATGTCACATCTCCTTTGTGGAA
AGTGACTGGTAAAGGAGAGAGAACAAAACTGGAGGAACGTAAAGTCTTCAG
CCACCTGGTTTAATTTATTCAAGAGTGATTAATCCTAGATGAGAAAAAGAATT
GAAATGGATCGGAAAAAAATGAAAGTGCATTGGCCGGGAATCGAACCCGGG
CCTCCCGCGTGGCAGGCGAG 
 
 -647 (Existing EcoRI site) to -71 bp 
O AATTCTACCACTGAACCACCAATGCTACTGTCAGCTAAAGACCTGCAGTATT
GTCTCTTAAAGCTCACTATCTCTGGCCATTCGCTAAGGAACCAGGCACCGTC
TTAAATCGCGGTTTGGAAAATATTTTGTTCAAGATAAAACTGTTTTAAGATAT
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ACGTGTATATATCTTATATATCTGTATTCGCATGGTAACATATCTTCGGCCTT
CCTGAGCCGCTGGGCTCTCAGCGGCCCTCCAAGGCAGCCCGCAGGCCCCT
GTGTGCCTCAGGGATCCGACCTCCCACAGCCCCGGGGAGACCTTGCCTCT
AAAGTTGCTGCTTTTGCAGCCTCTGCCACAACCGCGCGTCCTCAGAGCCAG
CCGGGAGGAGCTAGAACCTTCCCCGCATTTCTTTCAGCAGCCTGAGTCAGA
GGCGGGCTGGCCTGGCGTAGCCGCCCAGCCTCGCGGCTCATGCCCCGAT
CTGCCCGAACCTTCTCCCGGGGTCAGCGCCGCGCCGCGCCACCCGGCTGA
GTCAGCCCGGGCGGGCGAGAGGCTCTCAACTGGGCGGGAAGGTGCGGGA
AGGTGCGGAAAGGTTCG 
 
 -70 (Existing NruI site) to +48 
O CGAAAGTTCGCGGCGGCGGGGGTCGGGTGAGGCGCAAAAGGATAAAAAG
CCCGTGGAAGCGGAGCTGAGCAGATCCGAGCCGGGCTGGCTGCAGAGAA
ACCGCAGGGAGAGCCTCACT  
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Protocol for making pGL4.1 HSPA6 internal deletion constructs 
 The Agilent QuikChange Lightning Site Directed Mutagenesis kit (Cat 
#210518) was used  to generate the HSP deletion constructs (HSPA6 B, 
C, D, W, X, Y, and Z). As per the manufacturer’s instructions, ~100-150 bp 
can be accurately deleted from the sequence.   
 Deletion A was generated through “normal” cloning procedure. 
 pGL4.1 HSPA6 -647 deletion construct (B-D) primers.  
o B forward:  
CTGTTTTAAGATATACGTGTATATATCTTGCCTCTAAAGTTGCTGCTTTTGCA
GCC 
o B Reverse:  
GGCTGCAAAAGCAGCAACTTTAGAGGCAAGATATATACACGTATATCTTAAA
ACAG 
o C Forward:  
ACAGCCCCGGGGAGACGCCGCCCAGCCTCG 
o C Reverse:  
CGAGGCTGGGCGGCGTCTCCCCGGGGCTGT 
o D Forward:  
CGGGCTGGCCTGGCGTACGAAAGTTCGCGGC  
o D Reverse:  
GCCGCGAACTTTCGTACGCCAGGCCAGCCCG 
 pGL4.1 HSPA6 -647 deletion construct (A) primers.  
o A Forward:  
gatcGGTACCCTTATATATCTGTATTCGCATGGTAACATATC (KpnI site) 
o A Reverse:  
ttggAAGCTTAGTGAGGCTCTCCCTGCGG (HindIII site) 
 pGL4.1 HSPA6 -1230 deletion construct (W-Z) primers.  
o W Forward:  
CTCTGGCCTAACTGGCCGCAGTAGTTTACTCTCCACCTGAGTCC 
o W Reverse:  
GGACTCAGGTGGAGAGTAAACTACTGCGGCCAGTTAGGCCAGAG 
o X Forward:  
GGAGGTAGGTTGGACTGGAGCCTGCTCTGCGTCCTCCTTTCCCAGG 
o X Reverse:  
CCTGGGAAAGGAGGACGCAGAGCAGGCTCCAGTCCAACCTACCTCC 
o Y Forward:  
GAACATGAGGGACATCCCGACCGAGAGAGAACAAAACTGGAGGAAcG  
o Y Reverse:  
CGTTCCTCCAGTTTTGTTCTCTCTCGGTCGGGATGTCCCTCATGTTC 
o Z Forward:  
CCTTTGTGGAAAGTGACTGGTAAAGGAATTCTACCACTGAACCACC 
o Z Reverse:  
GGTGGTTCAGTGGTAGAATTCCTTTACCAGTCACTTTCCACAAAGG 
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Biotech center sequenced HSPA6 promoter internal deletion sequence 
 W deletion sequence (-1230 to -1084) 
o gatctgaatggaatGTTCTGGATTGAAGAAAGTGGGAAATGGCCTCAATTCACAAA
GTCACAACCTGATAAAAACCAGTGTGACTTTACTGCCCAGTGAACCCATCTC
GTCCTCCAGCCTTTAGGAGGTAGGTTGGACTGGAGCCTG 
 X Deletion sequence (-1083 to -928) 
o CAGTAGTTTACTCTCCACCTGAGTCCTGGTCTCCAGCTGGGAACCCACTTA
GGCCATAGAGAAAAACGCACACTGTGCCTCTCCACCGGGCCTCTGGAGAC
GAGGCTCCTCGGGGATACAAACAGTGGGGAGAACATGAGGGACATCCCGA
CCGTA 
 Y Deletion sequence (-927 to -808) 
o CTCTGCGTCCTCCTTTCCCAGGTGTTGCGTTCTCTCTTGGGCTGAGTGGCG
AGGTCTCTCCCGAGTCCCAGGGCCACAGTGCAATGTCACATCTCCTTTGTG
GAAAGTGACTGGTAAAGG 
 Z Deletion sequence (-807 to -648) 
O AGAGAGAACAAAACTGGAGGAACGTAAAGTCTTCAGCCACCTGGTTTAATTT
ATTCAAGAGTGATTAATCCTAGATGAGAAAAAGAATTGAAATGGATCGGAAA
AAAATGAAAGTGCATTGGCCGGGAATCGAACCCGGGCCTCCCGCGTGGCA
GGCGAG 
 A Deletion sequence (-647 to -479) 
O AATTCTACCACTGAACCACCAATGCTACTGTCAGCTAAAGACCTGCAGTATT
GTCTCTTAAAGCTCACTATCTCTGGCCATTCGCTAAGGAACCAGGCACCGTC
TTAAATCGCGGTTTGGAAAATATTTTGTTCAAGATAAAACTGTTTTAAGATAT
ACGTGTATATAT 
 B Deletion sequence (-478 to -347) 
o CTTATATATCTGTATTCGCATGGTAACATATCTTCGGCCTTCCTGAGCCGCT
GGGCTCTCAGCGGCCCTCCAAGGCAGCCCGCAGGCCCCTGTGTGCCTCAG
GGATCCGACCTCCCACAGCCCCGGGGAGAC 
 C Deletion sequence (-346 to -217) 
O CTTGCCTCTAAAGTTGCTGCTTTTGCAGCCTCTGCCACAACCGCGCGTCCT
CAGAGCCAGCCGGGAGGAGCTAGAACCTTCCCCGCATTTCTTTCAGCAGCC
TGAGTCAGAGGCGGGCTGGCCTGGCGTA 
 D Deletion sequence (-216 to -71) 
O GCCGCCCAGCCTCGCGGCTCATGCCCCGATCTGCCCGAACCTTCTCCCGG
GGTCAGCGCCGCGCCGCGCCACCCGGCTGAGTCAGCCCGGGCGGGCGAG
AGGCTCTCAACTGGGCGGGAAGGTGCGGGAAGGTGCGGAAAGGTTCG 
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APPENDIX 4 
TNIP1 Transcriptional Start Site (TSS)  
5’ RNA ligase-mediated rapid amplification of cDNA ends (5’ RLM-RACE)  
Total RNA was extracted from human cell cultures Caco-2, HaCaT, HeLa, 
HepG2, Jurkat, MCF7, SCC13, SCC25, normal dermal foreskin fibroblasts 
(FSFB), and scleroderma explant (Sclero expl) fibroblasts using RNeasy 
(QIAgen, Valencia, CA). 5’ RLM-RACE was performed with the GeneRacer 
system (Invitrogen). Briefly, 1-2 μg of total RNA was treated with calf intestinal 
phosphatase and then tobacco acid pyrophosphatase, ligated to the GeneRacer 
RNA oligonucleotide sequence, and then reverse transcribed using SuperScript 
III RT. PCR amplification of the resulting cDNA was performed using two sets of 
primers. PCR products were cloned into pCR4-TOPO vector and sequenced. 
 
Mapping TNIP1’s transcriptional start sites (TSS) 
The TNIP1 gene sequence is increasingly GC rich and without a recognizable 
TATA box nearing the cluster of expected TSS defined by cap-analysis of gene 
expression (CAGE) database extractions [16,30]. These characteristics are 
consistent with this region being dispersed rather than focused type of promoter 
and furthermore predict multiple transcription start sites over a 50-100 nucleotide 
region [31]. Because of its reliance on 5’ capped mRNA, the RLM-RACE 
approach is advantageous in determining bona fide TSS. Using it and RNA from 
human cell cultures, we mapped multiple TSS to the 5’ region of the TNIP1 gene 
(Fig 1A). All but one of the TSS reside in either of two alternative first exons (Fig 
1B & 1C) [32,33].  
 
A TSS in exon 2 (Fig 1D) is previously unknown. Among the cell types 
examined it is characteristic for MCF-7 cells; no other cell’s TSS mapped to this 
point in exon 2 nor did MCF-7 cells produce message from either of the two 
major TSS clusters. Within each TSS cluster, actual start sites spanned lengths 
of ~30 or ~90 nucleotides. Both of these clusters experimentally validate our 
CAGE-mapped TSS [16]. TSS in the 90 nucleotide span overlap the point 
previously used as +1 in numbering ~600bp [15] and ~6000bp [16] promoter 
clones and are associated with long exon 1.  For consistency with these reports, 
we have retained such numbering in this study (+1, open arrow, Fig 1C). The 
other TSS cluster is ~6000 nucleotides upstream of this region suggestive of an 
alternative promoter. Interestingly, while TSS for some cells (normal dermal 
fibroblasts; immortalized, non-tumorigenic HaCaT keratinocytes; malignant 
keratinocyte lines SCC13 or SCC25; Caco2; and adenocarcinoma HeLa cells) 
mapped to both regions, for other cells, (HepG2 and Jurkat), the TSS cluster 
mapped to only the upstream region.  
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Mapping the TSS of TNIP1. A. Schematic illustration of the TNIP1 gene including 
alternative first exons. Gray dotted line denotes our 6 kb promoter. B,C & D 
partial sequences showing the multiple TSS for short exon 1, long exon 1 and 
exon 2 (resp.).  Our +1 is denoted in long exon 1 by the open arrow. (All 
untranslated regions are in lower case, and coding regions in upper case.)  
Nucleotide numbers in B,C & D reflect positions in the relative genomic sequence 
based on the assigning +1 in long exon as denoted above.  ★ denotes the 
location of the -131 and -150 Sp sites.   
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Appendix 5 
Experiment numbers for each figure  
Figure # 
Corresponding 
Experiment # 
Type of experiment 
2.1 76 Validation of TNIP1 overexpression 
2.2 top 47 TNIP1 overexpression microarray results 
2.2 bottom 68, 69, 71, 72, 
73, 84 
qPCR validation of the microarray 
2.5 53 Effect of TNIP1 overexpression on HSPs in HaCaT KCs 
2.6, 2.7 119 Effect of TNIP1 overexpression on KC in NHEKs 
3.1, 3.2 121, 195 Basal and heat-inducible expression of HSPs in HaCaT KCs 
3.3 197 Expression of HSPA6 in various cell types 
3.6 150 
Determining the transcriptionally regulated regions within the 
HSPA6 promoter 
3.7 187, 202 Localizing the repressible region within the HSPA6 promoter 
3.8 187, 188 
Localizing the basal and inducible regions within the HSPA6 
promoter 
3.9 193, 196 
Searching for transcription factor binding sites between -346 to 
-216 bp region of the HSPA6 promoter 
3.10 199 Characterization of the -244 bp AP1 site 
3.11 200 
EMSA binding analysis of AP1 proteins c-Jun and c-Fos to the 
-244 AP1 site 
3.12 193, 196 
Searching for heat responsive elements between -346 to -216 
bp region of HSPA6  
3.13 207 Characterization of the -284 bp HSE 
3.14, 3.16 201 EMSA binding analysis of HSF proteins to the -284 bp HSE  
3.15, 3.17 203 EMSA binding analysis of HSF proteins to a consensus HSE 
4.2 153, 162, 205 Analysis of the HSPA6 promoter truncation constructs + TNIP1 
4.3 206 Analysis of the HSPA6 promoter deletion constructs + TNIP1 
4.4 129 
Effect of TNIP1 overexpression on HSPs in heat stressed 
HaCaT KCs 
4.5 By Nora 
McHugh 
Effect of “short term” increased TNIP1 levels on HaCaT KCs 
viability and growth 
4.6 By Nora 
McHugh 
Effect of “long term” increased TNIP1 levels on HaCaT KCs 
viability and growth 
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